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Abstract 
Fibrin is a promising scaffold material for tissue engineered heart valves, as it is 
completely biological, allows for engineered matrix alignment, and is able to be 
degraded and replaced with collagen by entrapped cells. However, the initial fibrin 
matrix is mechanically weak, and extensive in vitro culture is required to create valves 
with sufficient mechanical strength and stiffness for in vivo function. Culture in 
bioreactor systems, which provide cyclic stretching and enhance nutrient transport, has 
been shown to increase collagen production by cells entrapped in a fibrin scaffold, 
accelerating strengthening of the tissue and reducing the required culture time. In the 
present work, steps were taken to improve bioreactor culture conditions with the goal of 
accelerating collagen production in fibrin-based tissue engineered heart valves using 
two approaches: (i) optimizing the cyclic stretching protocol and (ii) developing a novel 
bioreactor system that permits transmural and lumenal flow of culture medium for 
improved nutrient transport. The results indicated that incrementally increasing strain 
amplitude cyclic stretching with small, frequent increments in strain amplitude was 
optimal for collagen production in our system. In addition, proof of concept studies 
were performed in the novel bioreactor system and increased cellularity and collagen 
deposition near the lumenal surface of the tissue were observed. 
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Chapter 1. Introduction 
 
1.1. Anatomy and Function of Native Heart Valves 
The heart has four chambers that coordinate the pumping of blood throughout 
the pulmonary and systemic circulations and likewise four heart valves that act as one 
way valves, preventing backward flow of blood into each chamber. As shown in Figure 
1-1, blood in enters the right atrium through the superior vena cava and travels through 
the tricuspid valve into the right ventricle. Then the blood is pumped out through the 
pulmonary valve to the lungs where it is oxygenated. The oxygenated blood enters the 
left atrium and passes through the mitral valve into the left ventricle. From the left 
ventricle, the blood is pumped out through the aortic valve and delivered to the rest of 
the body. Each of these four heart valves is of key importance in maintaining the 
directional flow of blood through the heart. While the basic function of the four heart 
valves is the same, the hemodynamics and loading conditions are different. Each of the 
four valves has a unique location-specific anatomy which enables its function.1 
 
1.1.1. The Atrioventricular Valves 
The right atrium and ventricle and the left atrium and ventricle are connected by 
the tricuspid and bicuspid (mitral) valves, respectively. These two valves are referred to 
as the atrioventricular valves. Both atrioventricular valves consist of a valve annulus 
with leaflets. These leaflets are anchored to the ventricular walls by tendinous cords and 
the papillary muscles. During diastole, when the heart muscle is relaxed, blood flows 
2 
through the atrioventricular valves into the ventricles. During systole, the contraction 
phase, the leaflets close, preventing backflow of blood. The tendinous cords support the 
leaflets during systole and ensure coaptation. The tricuspid valve has three leaflets that 
are supported by three papillary muscle complexes while the mitral valve has two 
leaflets and two papillary muscle complexes. The leaflets of both the tricuspid and 
mitral valves are layered structures. The atrium facing surface of the leaflet, the atrialis 
layer, consists of aligned collagen and elastic fibers. Beneath the atrialis lies the 
spongiosia layer containing glycosaminoglycans (GAGs) and proteoglycans, which 
cushion the leaflets during closure. Finally, the fibrosa layer, consisting of aligned 
collagen fibers, provides the majority of the mechanical strength. The main cell type 
within the leaflet is the valvular interstitial cell (VIC) and both the atrial and ventricular 
surfaces of the leaflets are covered by valvular endothelial cells (VECs). The leaflets of 
the atrioventricular valves are attached to an annulus that is highly dynamic, changing 
shape throughout the cardiac cycle.2,3  
 
1.1.2. The Semilunar Valves 
The pulmonary and aortic valves direct the forward flow of blood from the 
ventricles to the lungs and body, respectively. Both valves are tri-leaflet valves, and 
because of the curved “half moon” shape of the junctions between the leaflets and the 
arterial wall, they are referred to as the semilunar valves. The pressure across the closed 
pulmonary valve is approximately 10 mmHg while the aortic valve sustains much 
higher pressure gradients of around 80 mmHg4 and has thicker leaflets than the 
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pulmonary valve.5 The valve leaflets are tri-layered structures consisting of the 
ventricularis layer (analogous to the atrialis in AV leaflets) which contains aligned 
collagen and elastic fibers, the shock absorbing spongiosa layer consisting of GAGs and 
proteoglycans, and the load bearing fibrosa layer containing aligned collagen fibers. As 
in the AV valves, the cells in the leaflets are comprised of VICs and VECs.2,3 
The collagen fibers in the fibrosa layer are primarily aligned from commissure 
to commissure, and this collagen alignment gives the leaflet greater strength and 
stiffness in the commissural direction as compared to the radial direction.2,6 The 
Young’s modulus for the native human aortic valve leaflet is approximately 15 MPa in 
the circumferential direction, while in the radial direction the Young’s modulus is only 
1-2MPa.6 During diastole, it is estimated that the leaflet strain in the radial direction is 
more than two times the strain in the circumferential direction, and this mechanical 
anisotropy is important for proper valve function under physiological loading.7-9 
 
1.2. Heart Valve Defects and Disease 
More than 85,000 heart valve related procedures are performed annually in the 
United States, and it is estimated that heart valve disease affects 2.5% of the population. 
While the prevalence of heart valve disease increases with age and is most prevalent in 
patients over 65, there are a variety of congenital heart defects that affect the valves of 
pediatric patients as well. The prevalence of congenital heart defects is approximately 8 
in 1000 live births, and many of these defects require extensive reconstruction or 
replacement of one or more of the heart valves.10 
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1.2.1. Congenital Heart Defects 
There several congenital heart defects that affect one or more of the heart valves 
and require valve repair or complete replacement. Atrioventricular septal defect is a 
condition in which the atrioventricular junction is malformed. Patients with this defect 
may have improperly formed tricuspid and mitral valves, and in many severe cases the 
tricuspid and mitral valves are combined into a common atrioventricular valve, instead 
of existing as two separate valves. In other congenital heart malformations patients may 
lack a tricuspid valve (tricuspid atresia) or suffer from insufficiency, malformation, or 
stenosis (narrowing) of one or more atrioventricular valves. The majority of the 
atrioventricular valve defects are repaired by restructuring the existing valves or re-
routing the circulation. Several of these repairs involve multiple surgeries over the 
course of the first several years of the patient’s life. 
Stenosis of the semilunar valves is one of the more commonly occurring 
abnormalities. Although this stenosis can take various forms, a two-leaflet (bicuspid) 
aortic valve is one of the most prevalent congenital malformations. This defect prevents 
the valve from opening fully, resulting in altered pressure and flow characteristics. 
Tetralogy of Fallot is another common congenital heart defect that affects the semilunar 
valves. In patients with Tetralogy of Fallot the pulmonary valve is typically stenotic 
with a small annulus and thickened leaflets. Reconstruction or replacement of the 
semilunar valves is often required, either as a neonate or later in life for patients with 
stenotic semilunar valves.11 
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1.2.2. Acquired Valvular Disease 
In addition to congenital valve defects, acquired valvular disease can also lead to 
valve insufficiency in adult patients. Heart valve disease is prevalent in the United 
States, comprising 10-20% of cardiac surgical interventions.12 Risk for valvular disease 
is associated with increased age, and as the average age of the population continues to 
increase, incidence of valvular disease is expected to rise. Mitral valve regurgitation is 
the most common valve disease, affecting 1.7% of the adult population in the U.S.10 
This condition is ameliorated by mitral valve repair or replacement. Another common 
valve affliction in older patients is the progressive calcification of the aortic valve 
leaflets resulting in stenosis. This narrowing of the valve opening produces an increase 
in ventricular pressure and in turn results in left ventricular hypertrophy, a process in 
which the left ventricular wall thickens to compensate for the increased pressure. Left 
untreated, severe aortic stenosis can result in heart failure. Once a patient begins 
showing symptoms of aortic stenosis, the only current treatment option is replacement 
of the aortic valve with a prosthetic.13 
 
1.3. Heart Valve Replacement: Current State of the Art 
For many pediatric and adult patients with malformed or deteriorated heart 
valves, valve replacement is the standard treatment. There are currently two options for 
replacement valves: mechanical prosthetic valves and bioprosthetic valves. These 
prosthetic valves have been used successfully for several decades, increasing life span 
and improving the quality of life for many patients. However, each of the currently 
6 
available options has a unique set of advantages and drawbacks. The current gold 
standard for mechanical prosthetic valve design is a bileaflet valve that was initially 
manufactured by St. Jude Medical. The valve is made from pyrolytic carbon, and it 
consists of two leaflets, which open and close in response to the pressure difference 
across the valve. While these prosthetics are highly durable, patients receiving 
mechanical valves require lifelong anticoagulation therapy, which creates a bleeding 
risk and may require changes in lifestyle. The alternative is a bioprosthetic valve, which 
typically consists of a fixed porcine valve or tissue. In some cases human tissue 
homografts or autografts may be used, though these are limited in availability. While 
bioprosthetic valves are more biocompatible and do not require chronic anticoagulation, 
the valves are not living tissue, and over time they are prone to calcification and 
deterioration.13 In addition, neither bioprosthetic nor mechanical prosthetic valves are 
capable of growth, which is particularly problematic for pediatric patients. With these 
drawbacks in mind, it is clear that there is room for innovative improvement in 
prosthetic heart valve design. 
 
1.4. Heart Valve Tissue Engineering: Current Approaches 
In order to address these shortcomings, researchers have begun work to develop 
a living tissue engineered heart valve (TEHV) that could be used as a replacement 
valve, particularly for young patients. Design criteria for a TEHV include sufficient 
mechanical properties, high durability, native-like hemodynamic behavior, and an 
ability to grow and adapt with the patient. The TEHV must also be non-thrombogenic 
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and non-immunogenic to prevent clot formation and immune rejection, respectively. 
Research groups have developed different methods to produce a TEHV that meets these 
demanding design criteria, but all approaches have certain aspects in common. All 
TEHVs are based on a scaffold material, which provides the mechanical support and 
correct heart valve geometry. These scaffold materials can be degradable synthetic 
polymers, such as polyglycolic acid or polylactic acid,14-16 or biopolymers like fibrin or 
collagen.17-19 In the classical tissue engineering approach, a TEHV is created by seeding 
or entrapping a relevant cell type, such as fibroblasts, mesenchymal stem cells, or 
smooth muscle cells, in the scaffold. This construct is then cultured in vitro, during 
which time the cells produce their own extracellular matrix (ECM) as the scaffold 
material is degraded.15-20 The cell-produced ECM components, specifically collagen, 
provide the mechanical strength necessary to maintain valve structure and function. 
Various biochemical and mechanical stimuli can be used to guide the maturation 
process of the TEHV during the in vitro culture period,20-24 and because a TEHV 
consists of living tissue, it has the ability to adapt and remodel in response to in vivo 
stimuli upon implantation.14, 25-29 
Historically, the bulk of TEHV research focused on developing methods to 
create cellular tissue, preferably containing autologous cells to avoid an adverse 
immune response.15-20, 28, 29 In this approach, a patient’s cells would be isolated and used 
to produce an implantable TEHV. After weeks of in vitro culture, the TEHV could then 
be implanted back into the same patient from whom the cells were isolated. In recent 
years, there has been increased research into developing a TEHV that is available “off-
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the-shelf,” eliminating the long wait time between cell isolation and heart valve 
implantation30-33 Decellularization, or removal of cells from the TEHV after in vitro 
culture, is one method of removing antigens that produce an immune response upon 
being implanted into a different patient. These TEHVs can be implanted acellular, or 
after seeding with patient specific cells such as mesenchymal stem cells (MSCs). 
Research is ongoing to determine how these decellularized TEHVs, both with and 
without seeded MSCs, are repopulated and remodeled by host cells in vivo. 
In the Tranquillo Lab, TEHVs are created using a fibrin gel scaffold with 
neonatal human dermal fibroblasts (nhdfs) entrapped. Our TEHVs are completely 
biological, as fibrin is a biopolymer, isolated from the blood, which undergoes 
controllable, natural enzymatic degradation. Fibrin scaffolds are additionally 
advantageous because the cell-mediated fibrin gel contraction can be used to achieve 
tissue anisotropy similar to that of the native heart valve root and leaflets.18 The 
entrapped nhdfs are capable of remodeling and compacting the fibrin gel, and with the 
appropriate geometric constraints, the alignment of the fibrin fibrils and cell-produced 
ECM can be controlled.18,31 This is a major advantage over the commonly used 
isotropic synthetic polymer scaffolds, which do not recapitulate the native anisotropy. 
In the original fibrin-based TEHV design, a suspension of nhdfs in fibrinogen and 
thrombin was injected into a tri-leaflet or bi-leaflet Teflon mold with semilunar valve 
geometry. After several weeks of in vitro culture, the nhdfs compacted and aligned the 
fibrin fibrils around the mold surfaces and replaced the initial fibrin gel with aligned 
collagen. The resulting TEHV had two or three leaflets extending from a cylindrical 
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root segment and was composed primarily of cell produced collagen. Due to the 
geometrical constraints of the mold, the collagen was aligned circumferentially in the 
root segment and from commissure to commissure in the leaflets, thus mimicking the 
collagen alignment in native semilunar valves.18 
In the current approach, fibrin based engineered tissue tubes are formed, and 
after several weeks of in vitro culture, the tubes consist mainly of cell-produced 
collagen and have near native strength and stiffness. The tubes are allowed to shorten 
axially but are constrained by an inner mandrel in the radial direction; therefore, this 
collagen is primarily aligned in the circumferential direction. At this point, the tubular 
constructs are decellularized and placed over a three post frame as shown in Figure 1-2. 
Under back pressure, the tube collapses over the frame, forming a tri-leaflet valve that is 
capable of opening and closing in response to pressure gradients. When the tube is 
collapsed over the frame, the collagen alignment is from commissure to commissure, 
similar to the native heart valve.31 This acellular engineered tissue is capable of being 
recellularized either in vitro, by seeded mesenchymal stem cells30 or in vivo by host cell 
invasion after implantation.32 
 
1.5. Mechanical Conditioning of Tissue Engineered Heart Valves 
For most current TEHV designs, extensive in vitro culture is required to produce 
a valve with sufficient mechanical strength and stiffness for implantation.15-20, 24, 31 This 
process is particularly important in fibrin-based TEHVs, which initially have low 
mechanical strength and stiffness.18, 24 Often culture periods of several months are 
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required to achieve the desired properties, and this long term culture can be costly. With 
this in mind, several groups have developed bioreactors that provide mechanical stimuli 
to aid in tissue formation and accelerate TEHV maturation. A variety of mechanical 
stimulation modes including shear flow, transmural flow, static stretch, cyclic 
mechanical stretching, and flexure have been used to improve tissue formation and 
maturation.16,19,20,22,24 A TEHV is a complex, three-dimensional structure, and fluid 
flow through a TEHV results in a combination of these stimulation modes. Due to the 
complexity of the system, the optimal mechanical conditioning protocol is still 
unknown. 
Several research groups have developed pulse duplicator flow loop systems, 
designed to mimic in vivo conditions, and have seen improved mechanical properties in 
their TEHVs.20,34 However, the loading in these systems is complex and difficult to 
control as the tissue remodels and TEHV properties change. Rather than attempting to 
replicate physiological conditions, some research groups have developed bioreactors to 
apply well-defined mechanical stimulation to TEHVs. Mol et al. developed a Diastolic 
Pulse Duplicator system in which pulsatile back pressure was applied to coapting 
leaflets, and they observed qualitative improvement in tissue formation using this 
simpler loading scheme.16 Syedain et al. developed a pulse-stretch bioreactor in which 
the TEHV is placed inside a latex tube and cyclically distended by the injection and 
removal of culture medium from both ends of the device. This system facilitates the 
application of controlled cyclic stretching of the root and leaflets, as the distension is 
determined by the stiffer properties of the latex tube rather than the changing properties 
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of the developing tissue. By incrementally increasing the root distension from 5% to 
15% over a three week conditioning period, they were able to increase the 
circumferential ultimate tensile strength (UTS) and Young’s Modulus of the leaflets by 
97% and 77%, respectively, compared to statically cultured controls.24 
In our group’s current approach, a modification of this pulse-stretch bioreactor is 
used to mechanically condition the tubular tissue constructs before they are 
decellularized and placed over the three-post frame. In this bioreactor, tubular fibrin-
based tissues are placed on the outside of a latex support sleeve and attached to two 
custom end pieces. Cyclic stretching is achieved by the injection of culture medium into 
the lumen of the latex tubing.31,35 A schematic of this bioreactor is shown in Figure 1-3. 
Advantages of this system include well-controlled cyclic stretching, simple assembly, 
and ease of sterilization between experiments. 
Although a variety of cyclic stretching bioreactors have been developed to 
strengthen and reduce the culture time of TEHVs, the optimal stretching protocol for 
accelerated tissue formation has not been well characterized. While there has been some 
study of the effects of stretch magnitude and duration on the collagen production 
pathway in various fibroblast-like cells,36-46 reported results have been highly variable, 
and a thorough investigation of cell response to cyclic stretching has not been 
performed. Additionally, several of the investigations into cyclic stretching induced 
collagen production have been performed in two-dimensional systems,40,43 which may 
not necessarily translate to three-dimensional tissue-engineered constructs. Currently, 
seven to eight weeks of in vitro culture is required for fibrin-based TEHVs to reach near 
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physiological strength and stiffness. Long term in vitro culture is expensive, particularly 
for these large tubular tissue constructs, so a reduction in the required culture duration is 
highly desirable. The work presented here took steps to improve the effectiveness of 
bioreactor culture both by optimizing the cyclic stretching regimen and modifying the 
bioreactor to improve nutrient transport, ultimately aiming to accelerate collagen 
deposition and produce mechanically robust TEHVs more quickly and cost effectively. 
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1.6. Figures 
 
 
Figure 1-1. 
Flow of blood through the human heart is regulated by the four heart valves, the 
tricuspid, pulmonary, bicuspid, and aortic valves. Adapted from [1]. 
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Figure 1-2.  
(a) Schematic of tubular heart valve construction and images of the valve in the (b) 
closed and (c) open configurations. Adapted from [31] 
 
 
Figure 1-3. 
Image (a) and schematic (b) of the current Tranquillo lab bioreactor for cyclically 
stretching large diameter tissue tubes. Medium is injected into the lumen of the latex by 
a reciprocating syringe pump causing cyclic distension of the latex sleeve and tissue 
construct. The syringe is refilled from the surrounding medium through a 3-way valve. 
Adapted from A. Weston. 
(a) (b) 
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Chapter 2. The Effects of Constant Amplitude, Intermittent, and 
Incrementally Increasing Strain Amplitude Cyclic Stretching on 
ERK1/2 and p38 Signaling in Dermal Fibroblasts 
  
2.1. Introduction 
Mechanical conditioning is a widely employed method for obtaining the desired 
properties and function in engineered tissues. In engineered heart valves, arteries, 
ligaments, and skeletal muscle, where high mechanical strength is a requirement, cyclic 
mechanical stretching regimens have been used to induce cells to increase their 
production and maturation of collagen.16,19,24,35,36,41,42,45 Collagen is the major load 
bearing component in most native tissues, and increased collagen content is highly 
correlated with an increase in strength and stiffness in engineered tissues.35,36,42,45,47,48  
While cyclic stretching regimens are a common step in many tissue engineering 
fabrication processes, much is still unknown about the mechanism through which 
stretching results in increased collagen content, and thus the optimal cyclic stretching 
protocol may not be employed. The need for optimized cyclic stretching protocols is 
particularly crucial in attaining suitable properties in engineered tissues based on a 
sacrificial fibrin gel scaffold. Fibrin is an attractive scaffold biomaterial, as it is 
completely biological, degradable, can be cast in various geometries, and can be aligned 
and remodeled by entrapped cells.49 However, a fibrin gel has extremely low strength 
and stiffness compared to native collagenous tissues, and creating a fibrin-based tissue 
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with sufficient mechanical stiffness and strength for in vivo function absolutely requires 
stimulating an increase in the cellular production of collagen.  
The success of constant amplitude cyclic stretching protocols in increasing 
cellular collagen production is limited by adaptation of the cells to the applied 
mechanical stimulus.41,42 In order to combat the negative effects of adaptation, various 
stretching regimens have been employed including incrementally increasing strain 
amplitude approaches42 as well as intermittent stretching, in which tissues are exposed 
to alternating periods of cyclic stretching and static culture.36,41 These perturbations to 
constant amplitude cyclic stretching allow the cells to be re-stimulated by either 
subsequent applications of stretching after a rest period or an increment in the applied 
stretch amplitude. Previous studies have demonstrated that phosphorylation of 
extracellular signal-regulated kinase 1/2 (ERK1/2) occurs rapidly following the onset of 
cyclic stretching of cardiovascular fibroblasts, and that this activation is required for 
cyclic-stretching induced collagen transcription.43 Similar signaling behavior has been 
observed for a variety of cell types in response to cyclic stretching, and it has been 
shown that the ERK1/2 activation response is transient, with peak activation occurring 
5-20 minutes after the onset of cyclic stretching and return to baseline level by 1 
hour.41,43,50-52 Although this adaptation occurs rapidly, it has been shown that ERK1/2 
can be reactivated following a rest period by a second onset of stretching.41 This 
suggests that it may be possible to repeatedly activate ERK1/2 to maximize the benefit 
of cyclic stretching. 
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The aims of this study were (i) to characterize the transient signaling response of 
fibroblasts to constant amplitude cyclic stretching by monitoring phosphorylation of 
both ERK1/2 and p38, a known ERK1/2 inhibitor, and (ii) to determine the timing and 
nature of the perturbation to constant amplitude cyclic stretching that is required for 
ERK1/2 reactivation. This work provides insight into the signaling response of 
fibroblasts undergoing cyclic stretching and offers guidance in selecting a mechanical 
conditioning protocol to accelerate collagen production in fibrin-based engineered 
tissues. 
 
2.2. Methods 
 
2.2.1. Cell Culture 
Neonatal human dermal fibroblasts (Lonza) were expanded in 50:50 
DMEM:F12 with 15% fetal bovine serum (Hyclone), 100 µg/ml streptomycin, and 100 
U/ml penicillin. Cells were grown to confluence and harvested for use at passage 7.  
 
2.2.2. Fibrin-based Tissue Construct Fabrication and Culture 
Fibrin gels with entrapped cells were created by suspending neonatal human 
dermal fibroblasts in DMEM and then mixing the cells with a 20 mM HEPES-buffered 
saline solution containing bovine fibrinogen (Sigma). In order to form a fibrin gel, a 
solution of bovine thrombin (Sigma) and CaCl2 in DMEM was added to the 
fibrinogen/cell solution. The solution was injected into 6-well circular tissue-train plates 
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(Flexcell® International), which have a circular foam insert that anchors the gel around 
its circumference. The volume of gel in each well was 2 ml. The final composition of 
the gel was 6.7 mg/ml fibrinogen, 500,000 cells/ml, 0.8 U/ml thrombin, and 5 mM 
CaCl2. The discs were allowed to gel for 6 minutes in the tissue culture hood at 20°C 
and an additional 24 minutes in a standard cell culture incubator at 37°C. After the 
solutions had gelled, DMEM supplemented with 10% fetal bovine serum, 100 µg/ml 
streptomycin, 100 U/ml penicillin, 0.25 µg/mL amphotericin B, 50 µg/ml ascorbic acid, 
and 2 µg/ml insulin was added (5 ml per well). Medium was replaced three times 
weekly. All constructs were cultured statically for one week before cyclic stretching 
regimens were applied. 
 
2.2.3. Cyclic Stretching of Tissue Constructs 
Uniaxial cyclic stretching was applied to the constructs using the FX-5000 
Tension System and Arctangle® loading station (Flexcell® International). The 6-well 
tissue-train plates have a flexible silicone bottom which was uniaxially stretched by the 
application of vacuum beneath the wells (Figure 2-1,a-d).  All cyclic stretching 
regimens were applied using a square waveform with a frequency of 0.5 Hz, and a duty 
cycle of 15%. The applied strain was validated for the fibrin constructs using digital 
image correlation as described by Raghupathy et al.53 Relatively uniform uniaxial strain 
was applied to a central rectangular area approximately 13 mm by 17 mm, and this 
strain was consistently applied throughout the duration of the experiments. While there 
was some heterogeneity in the strain field in this region, the strain was primarily 
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uniaxial and, averaged over the region, was in good agreement with the set point. Four 6 
mm biopsy punches were taken from this region for characterization (Figure 2-1,e). The 
constructs remained in a standard cell culture incubator for the duration of the stretching 
regimens.  
 
2.2.4. Protein Extraction 
At harvest, constructs were excised from the wells, rinsed in phosphate buffered 
saline (PBS), and frozen at -80°C. Samples were lysed by sonication in Bicine/CHAPs 
buffer with 1X Aqueous and DMSO Inhibitor Cocktails (ProteinSimple) and placed in 
an end over end mixer at 4°C for 30 minutes. The lysates were purified by 
centrifugation at 13,000 rpm for 15 minutes at 4°C. The protein concentrations were 
determined using a bicinchoninic acid assay (Pierce). 
 
2.2.5. Nano-fluidic Proteomic Immunoassay for ERK1/2 Phosphorylation 
Nano-fluidic immunoassay experiments were performed on the purified lysates 
using a Nanopro 1000 system (ProteinSimple, Mayo Proteomics Core Facility).54 
Lysates were used at a final concentration of 100 µg/ml. Briefly, this system separates 
proteins by isoelectric point within a small capillary, and fixes them to the inner surface 
of the capillary after separation. This sensitive separation allowed differentiation 
between the isoforms of the ERK1/2 protein. Separated proteins were incubated with a 
pan-ERK1/2 antibody at a dilution of 1:200 for 2 hours. This antibody binds to all 
isoforms of ERK1/2, so unphosphorylated, single phosphorylated, and double 
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phosphorylated ERK1 and ERK2 could be probed using a single antibody (Figure 2-2). 
Proteins were incubated in HRP-conjugated secondary antibody at 1:100 for 1 hour 
followed by chemiluminescence reagent. The emitted light was detected through the 
wall of the capillary with a 30 second exposure by a camera, outputting 
chemiluminescence intensity as a function of isoelectric point. Peak identification of the 
ERK1/2 isoforms was verified by registry with peaks from HeLa control samples and 
isoform specific antibodies. All antibodies and reagents were acquired from 
ProteinSimple. The results were quantified using Compass software (version 1.8.1) 
using the peak area function. Ratios of phosphorylated ERK1/2 (all phosphorylated 
isoforms) to total ERK1/2 (all isoforms) are reported and normalized as indicated in 
corresponding figure captions. 
 
2.2.6. Western Blot for p38 
Reducing SDS-PAGE was used to separate 20 µg of total protein per well. The 
proteins were transferred to a nitrocellulose membrane and blotted for phosphorylated 
p38 (Cell Signaling Technologies #9211) and total p38 (Cell Signaling Technologies 
#9212). The blots were blocked for 1 hour in 5% dry milk, 0.1% Tween-20 in PBS, and 
then incubated for 1 hour in primary antibody at 1:1000 in tris-buffered saline with 
0.1% Tween-20 (TBS-T) and 5% bovine serum albumin. Blots were washed with TBS-
T and incubated for 1 hour in secondary antibody (1:2000 anti-rabbit IgG, GE 
Healthcare) in the blocking solution. Finally blots were washed in TBS-T and TBS and 
developed using Luminata Classico enhanced chemiluminesence (EMD Millipore). 
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Films were scanned and digitized, and ImageJ (NIH) was used to quantify band density. 
The ratio of phosphorylated p38 to total p38 is reported and normalized as indicated in 
corresponding figure caption.  
 
2.2.7. Statistics 
All figures show mean ± standard deviation with at least n=3 per group. 
Significance was determined using Student’s t-test for two groups and one-way 
ANOVA for more than two groups with the Tukey post-hoc test in GraphPad Prism 
software for Windows with p<0.05 reported as significant. Symbols or bars are used to 
indicate significant differences and explained in the corresponding figure captions. 
 
2.3. Results 
 
2.3.1. ERK1/2 and p38 MAPK phosphorylation time course: constant amplitude 
stretching 
 To determine the activation time course of ERK1/2 and p38 MAPK, samples 
were stretched continuously with 5% strain amplitude for 15 minutes, 1, 3, and 6 hours. 
At each time point stretched samples (n=3) and static controls (n=3) were harvested. 
Cyclic stretching resulted in peak phosphorylation of both ERK1/2 and p38 at 15 
minutes (Figure 2-3a,b). By 1 hour, ERK1/2 phosphorylation was only slightly elevated 
above static levels, while p38 phosphorylation remained elevated until the 6 hour time 
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point. Original Western blots for phosphorylated and total p38 are shown in Figure 2-
3c. 
 
2.3.2. ERK1/2 pathway activation: strain amplitude dependence 
In order to study the dependence of ERK1/2 phosphorylation on strain 
amplitude, samples were stretched with either 5% or 10% strain amplitude (n=3 per 
group). At 15 minutes stretched samples and static controls were harvested. Both 5% 
and 10% amplitude cyclic stretching resulted in ERK1/2 activation at 15 minutes, and 
there was no difference in the magnitude of activation between the two strain 
amplitudes (Figure 2-4). Note that each signaling experiment was carried out separately, 
so small discrepancies in the maximal ERK1/2 activation value are likely due to inter-
experiment variation. 
 
2.3.3. ERK 1/2 pathway reactivation: intermittent stretching 
 According to the determined ERK1/2 phosphorylation time course, peak 
phosphorylation was achieved at 15 minutes, after which point the cells were no longer 
responsive to the constant amplitude cyclic stretching. In order to determine how soon 
the pathway could be reactivated by a second onset of cyclic stretching, samples were 
stretched with 5% strain amplitude for 15 minutes and allowed to rest for 15 minutes, 3 
hours, or 6 hours (n=3 per group). Following the rest period, the samples were stretched 
with 5% strain amplitude for an additional 15 minutes before harvest. ERK1/2 was 
unable to be reactivated fully after 15 minutes of rest, and there was a trend of 
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increasing reactivation up to the 6 hour time point where full reactivation was achieved 
(Figure 2-5a).  
Next we tested various stretching durations within the 6 hour refractory period. 
Samples were stretched with 5% strain amplitude for 15 minutes, 1 hour, or 5 hours and 
then sat statically for the remainder of the 6 hour period (5 hours 45 minutes, 5 hours, 
and 1 hour, respectively). Then all samples were re-stimulated with 5% amplitude 
cyclic stretching for 15 additional minutes and harvested (n=3 per group). In all three 
groups, regardless of the stretch/rest durations within the 6 hour period, ERK1/2 was 
reactivated (Figure 2-5b). 
 
2.3.4. ERK1/2 pathway reactivation: incrementally increasing strain amplitude 
stretching 
 Similarly, we sought to investigate the effects of an increase in strain amplitude 
on ERK1/2 phosphorylation. Samples were stretched with 5% amplitude for 1 or 6 
hours, at which point the strain amplitude was increased to 10%. Samples were 
harvested (n=3 per group) immediately before and 15 minutes after the increment in 
strain amplitude. It was determined that stretching-induced ERK1/2 phosphorylation 
was only achieved by increasing the strain amplitude at 6 hours; the cells did not 
respond to the increment at the 1 hour time point (Figure 2-6). The experiment was 
repeated with an increment in strain amplitude of only 1% (5% to 6% at 6 hours), and 
full ERK1/2 activation was also achieved. 
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2.4. Discussion 
In this model system for a fibrin-based engineered tissue, 5% strain amplitude 
cyclic stretching resulted in transient phosphorylation of both ERK1/2 and p38 MAPK 
with peak phosphorylation at 15 minutes for both. Phosphorylation of ERK1/2 returned 
to near-static levels by 1 hour, while p38 phosphorylation remained elevated for at least 
3 hours. The magnitude of ERK1/2 activation at 15 minutes did not depend on the strain 
amplitude. Reactivation of ERK1/2 was achieved either by (i) the onset of an additional 
5% amplitude stretching period after 6 hours of static culture, or (ii) an increment of 1% 
in the strain amplitude after 6 hours of constant amplitude cyclic stretching.  
The transient ERK1/2 activation in response to 5% continuous stretching noted 
above has been observed on a similar time scale for a wide variety of cell types in both 
two-dimensional and three-dimensional culture.41,43,50-52 In addition, our finding that the 
strain amplitude did not affect ERK1/2 activation has also been observed for Achilles 
tendon fibroblasts in an engineered tendon model subjected to strain amplitudes of 
2.5%, 5%, and 10%.41 As phosphorylation of ERK1/2 has been shown to be necessary 
for stretch-induced up-regulation of collagen transcription by cardiac fibroblasts,43 it 
was hypothesized that some perturbation to constant amplitude cyclic stretching may be 
able to repeatedly activate ERK1/2 and increase collagen synthesis for the dermal 
fibroblasts in our fibrin-based engineered tissues.  
It was determined that the dermal fibroblasts exhibited a 6 hour refractory period 
before ERK1/2 could be re-stimulated, either by the onset of an additional stretching 
period or an increment in the strain amplitude. Paxton et al. obtained a similar result in 
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their engineered tendon system in which rat Achilles tendon fibroblasts also exhibited a 
6 hour refractory period before ERK1/2 could be reactivated by intermittent cyclic 
stretching.41 In our system the durations of stretch and rest periods within the 6 hours 
did not affect ERK1/2 reactivation, so it appears that as long as the cells undergo a brief 
static period before a second onset of cyclic stretching, reactivation will be achieved. In 
addition, it was found that an increment in strain amplitude of only 1% was able to 
reactivate ERK1/2 after 6 hours of constant amplitude cyclic stretching. 
In order to provide additional insight into ERK1/2 dynamics, we also 
characterized the time course of p38 phosphorylation in our system. p38 activation has 
been implicated in inhibiting ERK1/2 and thus having negative effects on stretch-
induced collagen production. Papakrivopoulou et al. demonstrated that constitutively 
active p38 reduced promoter activity of procollagen1 α1, and that the combination of 
cyclic stretching and inhibition of p38 activation increased procollagen1 α1 
transcription in cardiac fibroblasts.43 In our same fibrin-based engineered tissue, we 
showed that drug inhibition of p38 activation (SB 203580) increased stretching-induced 
ERK1/2 phosphorylation and collagen deposition.55 In the present study, p38 
phosphorylation was maximal after 15 minutes of 5% amplitude stretching, but its 
phosphorylation duration was longer than that of ERK1/2, returning to static levels only 
at the 6 hour time point. Transient phosphorylation of p38 by cyclic stretching has been 
observed in other two-dimensional and three-dimensional systems as well.41,43 It is 
proposed that the cell’s refractory period for ERK1/2 activation may be caused by the 
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prolonged p38 phosphorylation and alleviated by the return of p38 to basal levels at 6 
hours. 
In summary, the nature ERK1/2 and p38 activation in response to cyclic 
stretching has been characterized for dermal fibroblasts in a fibrin-based engineered 
tissue. It was determined that ERK1/2 activation occurs within only the first hour of 
cyclic stretching, and the pathway can only be reactivated after a 6 hour refractory 
period. The ERK1/2 phosphorylation dynamics suggest that two optimized cyclic 
stretching regimens can be applied to fibrin-based engineered tissues: (i) an intermittent 
regimen in which cells are re-stimulated by cyclic stretching periods every 6 hours and 
(ii) an incremental regimen in which the strain amplitude is increased by 1% after no 
less than 6 hours of constant amplitude cyclic stretching. It is hypothesized that 
application of these regimens, which repeatedly activate ERK1/2, will accelerate 
collagen deposition by the fibroblasts in our engineered tissues. Long-term application 
of these cyclic stretching regimens is presented in Chapter 3. 
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2.5. Figures 
 
 
Figure 2-1.  
Schematic of Flexcell® tension system for uniaxial cyclic stretching. (a) and (b) depict 
the unstretched top and side views, respectively, for a single well. The stretched 
configuration, produced by the application of vacuum beneath the well, is shown in (c). 
A sample fibrin-based tissue construct is shown in (d), secured to the perimeter of the 
silicone membrane by a foam ring with the black bar indicating 1 cm. The strain field is 
shown for 5% applied strain (e). For analysis, four 6 mm biopsy punches were taken 
from the uniaxially stretched region (blue rectangle). 
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Figure 2-2. 
Chemiluminescence intensity versus isoelectric point for static (blue) and 5% 
continuously stretched (green, with larger phosphorylated peaks) samples at 15 minutes. 
Peak identification was validated with HeLa control lysates and isoform specific 
antibodies. 
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Figure 2-3. 
(a) ERK1/2 and (b) p38 phosphorylation time courses during continuous cyclic 
stretching with 5% strain amplitude. All data are normalized to the 15 minute static 
value. Horizontal bars indicate differences (p<0.05) using Student’s t-test between time-
matched stretched and static samples (n=3 per group). (c) Representative Western blots 
for phosphorylated and total p38. 
(c) 
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Figure 2-4. 
ERK1/2 phosphorylation after 15 minutes of static culture, 5% constant amplitude 
cyclic stretching, or 10% constant amplitude cyclic stretching. All data are normalized 
to the 15 minute static value. Horizontal bars indicate differences (p<0.05) using one-
way ANOVA with Tukey post hoc test (n=3 per group). 
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Figure 2-5. 
(a) Reactivation of ERK1/2 15 minutes after onset of a second cyclic stretching period 
following rest durations of 15 minutes, 3 hours and 6 hours. ERK1/2 activation at the 
end of the initial 15 minute stretch is also shown. All data are normalized to the 15 
minute static value. Solid horizontal bars indicate differences (p<0.01) and dashed 
horizontal bars indicate trends (p<0.09) using one-way ANOVA with Tukey post hoc 
test (n=3 per group). (b) Reactivation of ERK1/2 15 minutes after onset of a second 
cyclic stretching period following stretch/rest durations of 0:15/5:45, 1:00/5:00, and 
5:00/1:00. All times are given in (hh:mm), and data are normalized to the 15 minute 
static value. Horizontal bars indicate differences (p<0.05) using Student’s t-test between 
paired pre/post-stretching groups (n=3 per group). 
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Figure 2-6. 
Activation of ERK1/2 15 minutes following an increment in the strain amplitude. All 
data are normalized to the pre-perturbation value immediately prior to the strain 
increment. Horizontal bars indicate differences between groups (p<0.01) using one-way 
ANOVA with Tukey post hoc test (n=3 per group). 
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Chapter 3. The Effects of Optimized Intermittent and Incremental 
Cyclic Stretching Regimens on Collagen Deposition by Fibroblasts in 
an Engineered Tissue 
 
3.1. Introduction 
As discussed in Chapter 2, mechanical conditioning is a crucial step in the 
fabrication of engineered tissues where high mechanical strength and stiffness are 
required, such as heart valves, arteries, ligaments, and muscle. In the previous chapter, 
dermal fibroblasts’ response to cyclic stretching at the cell signaling level was 
discussed, and several optimized regimens were proposed to maximize activation of 
ERK1/2, which has been implicated as an important early step in the collagen 
production pathway for fibroblasts undergoing cyclic stretching. While the cell 
signaling studies provided insight into cells’ early response to cyclic stretching, the 
collagen production pathway is complex, involving many more components than just 
ERK1/2 and p38. Although it is hypothesized that maximizing ERK1/2 activation will 
lead to an increase in collagen transcription and ultimately collagen deposition, it is 
certainly not guaranteed, and the downstream responses must be thoroughly studied. 
No single study has provided a comprehensive overview of cells’ response to 
cyclic stretching from signaling to deposition. However, a variety of downstream 
responses have been investigated for fibroblast-like cells including transcription of 
genes involved in collagen synthesis, maturation, and remodeling,38-40,43 deposition of 
insoluble collagen,36-38,41,42 and collagen crosslinking.36-38 Although these studies 
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certainly provide valuable information, the majority have focused on a single point in 
the collagen production pathway, so they do not provide a complete picture of the 
cellular response.  
The aim of this study was to compare transcription and deposition of collagen in 
fibrin-based engineered tissues subjected to constant amplitude cyclic stretching and 
optimized intermittent and incrementally increasing strain amplitude regimens, which 
were chosen based on ERK1/2 activation dynamics. Both transcription of collagen types 
I and III, which are major components of native cardiovascular tissue, as well as total 
collagen deposition were studied. Combined with the signaling studies presented in 
Chapter 2, this study describes the effects of the three modes of cyclic stretching on 
fibroblasts in an engineered tissue environment throughout the entire collagen 
production process with the goals of understanding cyclic stretching-induced collagen 
production and accelerating collagen deposition in our engineered tissues.  
 
3.2. Methods 
 
3.2.1. Cell Culture 
Neonatal human dermal fibroblasts (Lonza) were expanded in 50:50 
DMEM:F12 with 15% fetal bovine serum (Hyclone), 100 µg/ml streptomycin, and 100 
U/ml penicillin. Cells were grown to confluence and harvested for use at passage 7.  
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3.2.2. Fibrin-based Tissue Construct Fabrication and Culture 
Fibrin gels with entrapped cells were created by suspending neonatal human 
dermal fibroblasts in DMEM and then mixing the cells with a 20 mM HEPES-buffered 
saline solution containing bovine fibrinogen (Sigma). In order to form a fibrin gel, a 
solution of bovine thrombin (Sigma) and CaCl2 in DMEM was added to the 
fibrinogen/cell solution. The solution was injected into 6-well circular tissue-train plates 
(Flexcell® International), which have a circular foam insert that anchors the gel around 
its circumference. The volume of gel in each well was 2 ml. The final composition of 
the gel was 6.7 mg/ml fibrinogen, 500,000 cells/ml, 0.8 U/ml thrombin, and 5 mM 
CaCl2. The discs were allowed to gel for 6 minutes in the tissue culture hood at 20°C 
and an additional 24 minutes in a standard cell culture incubator at 37°C. After the 
solutions had gelled, DMEM supplemented with 10% fetal bovine serum, 100 µg/ml 
streptomycin, 100 U/ml penicillin, 0.25 µg/mL amphotericin B, 50 µg/ml ascorbic acid, 
and 2 µg/ml insulin was added (5 ml per well). Medium was replaced three times 
weekly. All constructs were cultured statically for one week before cyclic stretching 
regimens were applied. 
 
3.2.3. Cyclic Stretching of Tissue Constructs 
Uniaxial cyclic stretching was applied to the constructs using the FX-5000 
Tension System and Arctangle® loading station (Flexcell® International) as described 
in Section 2.2.3. The constructs remained in a standard cell culture incubator for the 
duration of the stretching regimens.  
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3.2.3.1. Experimental Design: Collagen Transcription 
Collagen transcription was investigated for static control samples and three 
cyclic stretching regimens, shown in Figure 3-1. Constant strain amplitude (“constant”) 
samples were stretched at 5% strain amplitude for 48 hours. Incrementally increasing 
strain amplitude (“incremental”) samples were stretched at 5% amplitude for 24 hours 
followed by 6% amplitude for 24 hours. Intermittently stretched samples 
(“intermittent”) were stretched at 5% amplitude for 15 minutes, followed by a 6 hour 
static period, and this regimen was repeated for the duration of the study. The 
intermittent samples were harvested at 49 hours, which was exactly 24 hours after the 
onset of a stimulation period. This was done for consistency with the incremental 
treatment group in which the samples were harvested 24 hours after the final increment. 
 
3.2.3.2. Experimental Design: Collagen Deposition Experiment 1 
Collagen deposition was measured after two weeks for static control samples 
and samples subjected to constant amplitude (5% or 13.5% strain amplitude), 
intermittent (15 min at 5%, 6 hours static, repeat), and incremental (5%-13.5%, 
increment by ~1% every 24 hours) cyclic stretching regimens (n=6 per group, pooled 
from two experimental repeats). Due to limitations of the stretching system, the target 
1% increment in strain every 24 hours was not able to be achieved, and in the last 
several days of stretching, the increments decreased in magnitude. However, a 
measureable increase in strain was still applied every 24 hours. 
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3.2.3.3. Experimental Design: Collagen Deposition Experiment 2 
In order to compare intermittent regimens with various combinations of stretch 
and rest durations, collagen deposition was measured for samples stretched for three 
weeks with three different intermittent cyclic stretching regimens: (i) 15 minutes at 5% 
strain followed by 6 hours of rest, (ii) 1 hour of 5% strain followed by 6 hours of rest, 
and (iii) 3 hours of 5% strain followed by 3 hours of rest. Control samples were 
stretched continuously with 5% constant amplitude for three weeks. 
 
3.2.4. RNA Purification and cDNA Synthesis 
Samples were harvested for real-time PCR 48 hours after beginning the selected 
stretching regimens. For consistency, all tissues were harvested 24 hours after a 
perturbation (onset of stretching or increment in amplitude). Tissues were excised from 
the wells and stored in RNAlater (QIAGEN) at 4°C. Samples were sonicated in RLT 
Plus, separated by centrifugation, and purified using the RNeasy Plus purification kit 
(QIAGEN) following the manufacturer’s instructions. RNA concentration was 
measured by spectrometry (NanoDrop, University of Minnesota Biomedical Genomics 
Center). 275 ng of each RNA sample were reverse transcribed using SuperScript III 
reverse transcriptase (Invitrogen) and 100 ng of random hexamer primers. Controls 
without reverse transcriptase were also prepared for each sample. 
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3.2.5. Real-time PCR 
Real-time PCR was performed using the 7900HT Fast Real-time PCR system 
(Applied Biosystems, University of Minnesota Lillehei Heart Institute) using the cDNA 
equivalent of 14 ng RNA, forward and reverse primers at a concentration of 600 nM, 
and 1X SYBR Green reagent (KiCqStart, Sigma) in a total volume of 12.5 µL. Primers 
were (5’-3’): fGAPDH(CGCATCTTCTTTTGCGTCGCCAG), 
rGAPDH(TGACAAGCTTCCCGTTCTCAGCC), 
fCOL1A1(GCCAAGACGAAGACATCCCACCA), 
rCOL1A1(CACGTCATCGCACAACACCTTGC), 
fCOL3A1(AACGGTCTCAGTGGAGAACG), and 
rCOL3A1(CCACTCTTGAGTTCAGGATGG). 
Expression levels of collagen types I (COL1A1) and III (COL3A1) relative to static 
controls were determined by the comparative CT method with GAPDH used as the 
reference gene. 
 
3.2.6. Collagen and Cellularity Quantification 
Collagen content was quantified using a hydroxyproline assay with a conversion 
factor of 7.46 mg of collagen for 1 mg 4-hydroxyproline.56 A modified Hoescht assay 
was used to determine cellularity.57 
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3.2.7. Statistics 
All figures show mean ± standard deviation with at least n=3 per group. 
Significance was determined using Student’s t-test for two groups and one-way 
ANOVA for more than two groups with the Tukey post-hoc test in GraphPad Prism 
software for Windows with p<0.05 reported as significant. Symbols or bars are used to 
indicate significant differences and explained in the corresponding figure captions. 
 
3.3. Results 
 
3.3.1. Transcription of collagen types I and III in cyclically stretched samples 
 At 48 hours there were no differences in transcription of collagen I (p=0.11) or 
III (p=0.15) between the static, constant amplitude, intermittent, or incremental 
treatment groups (Figure 3-2) assessed using one-way ANOVA (n=5 per group, pooled 
from two experimental repeats). 
 
3.3.2. Collagen Deposition Experiment 1: Comparison of Constant Amplitude, 
Intermittent, and Incremental Regimens 
Total collagen per cell, based on cell number at harvest, was measured for 
tissues subjected to constant amplitude (5% or 13.5% amplitude), intermittent (15 min 
at 5%, 6 hours static, repeat), and incremental (5%-13.5%, increment by ~1% every 24 
hours) cyclic stretching regimens. After two weeks, an increase in collagen per cell was 
measured in the 5% constant amplitude, intermittent, and incremental treatment groups 
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compared to static controls (Figure 3-3). The incremental treatment group showed the 
greatest increase in collagen per cell, 72% over static controls and 37% over the 5% 
constant amplitude samples. There was no difference in collagen per cell between the 
5% constant amplitude and intermittent treatment groups. 
 
3.3.3. Collagen Deposition Experiment 2: Intermittent Stretch/Rest Durations 
 After three weeks of intermittent stretching, collagen per cell was measured in 
samples subjected to three different intermittent regimens: 15 min stretch/6 hours rest, 1 
hour stretch/6 hours rest, 3 hours stretch/3 hours rest (Figure 3-4). Data are shown 
normalized to continuously stretched controls. There were no differences in collagen 
per cell for the three regimens, and none of the intermittent regimens increased collagen 
deposition compared to continuously stretched controls. 
 
3.4. Discussion 
Based on the ERK1/2 data, intermittent and incremental regimens were selected 
to repeatedly activate ERK1/2 with the hypothesis that repeated activation would lead to 
increased collagen synthesis and deposition. After 48 hours there were no differences in 
mRNA expression of collagen type I or III between any of the treatment groups. After 
two weeks, incrementally stretched tissues had the most collagen per cell, while 
intermittent samples showed no improvement over their continuously stretched 
counterparts. In addition, there appeared to be no effect of intermittent stretch/rest 
duration on collagen production in the tissues. These data suggest that while ERK1/2 
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phosphorylation may be necessary for stretch-induced collagen transcription,43 it is not 
a sufficient predictor of final collagen content in this system. 
Based on the dynamics of ERK1/2 phosphorylation, intermittent and 
incremental regimens were designed to maximize ERK1/2 activation throughout the 
culture period. Intermittently stretched samples were subjected to repeated periods of 
5% amplitude cyclic stretching for 15 minutes followed by 6 hours of static culture. The 
incrementally stretched samples were initially stretched with 5% strain amplitude, and 
the strain was increased by approximately 1% every 24 hours. While an increment 
every 6 hours would have been able to reactivate ERK1/2 more frequently, our goal was 
to apply the cyclic stretching regimen to long-term culture, and if the strain was 
incremented every 6 hours for several weeks, the amplitude would soon have exceeded 
the capabilities of the Flexcell® system and likely damaged the tissue. The chosen 
intermittent and incremental regimens are within the capabilities of both this model 
system as well as our bioreactors for larger engineered cardiovascular tissues.31,35 
After 48 hours of static culture, 5% constant amplitude cyclic stretching, or the 
chosen intermittent and incremental regimens, there were no differences in mRNA 
expression of collagen types I and III. The 48 hour time point was chosen to allow 
differentiation between the regimens, and for consistency, intermittent and incremental 
samples were harvested 24 hours after a perturbation. In an engineered tissue strip made 
from polyglycolic acid seeded with vascular derived cells, Van Geemen et al. similarly 
observed only small differences in collagen type I and III mRNA after 24 hours of 
continuous stretching or 3 hours of stretching followed by 21 hours rest.39 However, in 
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cyclic stretching studies where cells are simply adhered to the elastic substrate, 
significantly increased expression of collagen type I and/or III mRNA by fibroblasts has 
been observed on a similar time scale.40,43 It is unknown whether this discrepancy is due 
to the nature of our system,  wherein cells may not be experiencing the applied strain 
due to strain-shielding by the fibrin, or if the increase in collagen transcription is 
transient and we have not yet identified the peak time point.  
The selected intermittent and incremental regimens were applied to fibrin-based 
tissues for two weeks along with 5% and 13.5% constant strain amplitude regimens and 
a static control. Incremental stretching was the most beneficial in our system, resulting 
in a 37-72% increase in collagen per cell over the other regimens. The benefits of 
incremental stretching have been demonstrated previously in our lab, as Syedain et al. 
found that incremental stretching (5% to 15% with a 2.5% increment every 3-4 days) 
increased collagen deposition and tissue strength and stiffness in tubular engineered 
tissues similarly prepared from dermal fibroblasts in a sacrificial fibrin gel.42 The 
current study suggests that this stretching regimen can be improved further by 
employing smaller, more frequent increments in strain amplitude.  
While intermittent stretching did increase collagen per cell compared to static 
culture, it did not result in further improvement over 5% constant amplitude stretching. 
In addition to the initial 15 minute stretch/6 hour rest regimen, two additional 
intermittent protocols (1 hour stretch/6 hour rest and 3 hour stretch/3 hour rest) were 
tested for three weeks, and none of them resulted in increased collagen per cell 
compared to continuously stretched controls. Rubbens et al. observed an increase in 
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collagen per cell at two weeks in their intermittently stretched samples (3 hours stretch, 
3 hours static) compared to static controls; however, a continuously stretched treatment 
group was not included in this study for comparison.36 In contrast to the present result, 
Paxton et al. found that intermittent stretching (10 minutes every 6 hours) increased the 
percentage of collagen in their fibrin-based “sinews” approximately 20% over 
continuously stretched samples.41 However, there were several differences that may 
account for this discrepancy including the different cell type (tendon vs. dermal 
fibroblasts), fibrin gel composition, and strain amplitude (1% vs. 5%), as well as the 
sinew geometry in which the cells were allowed to compact the tissue strand, rather 
than being anchored on all sides in a circular well. Although the ERK1/2 dynamics 
appear to be favorable for the intermittent regimens in the present study, it may be that 
the prolonged static period has detrimental effects on collagen deposition in our system. 
Additionally, nutrient transport may be enhanced via convection during cyclic 
stretching of the highly hydrated fibrin gel and developing tissue,58,59 so it is possible 
that the intermittent samples do not experience this nutrient and metabolite transport 
enhancement during the static periods, offsetting any benefit of repeated ERK1/2 
activation. 
Although ERK1/2 was being repeatedly activated in both intermittent and 
incremental stretching, only incremental stretching resulted in an increase in collagen 
per cell over both static samples and samples stretched with constant strain amplitude 
after two weeks. Clearly in our system, ERK1/2 phosphorylation alone is not a 
sufficient indicator of final collagen content. Additionally, transcription of collagen type 
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I and III after 48 hours does not seem to be predictive of collagen per cell at two weeks. 
It should be noted that the measured collagen content in a tissue is not only a function 
of collagen transcription, but also translation and the many intervening collagen 
processing and transport steps prior to incorporation into the extracellular matrix,60 as 
well as collagen degradation,61,62 all of which may also be affected by the different 
cyclic stretching regimens. 
The present study represents data for a single isolation of dermal fibroblasts. At 
various points in the study, an additional isolation was used alongside the original 
isolation (data included in Appendix A), and while ERK1/2 and p38 phosphorylation 
results were similar for both isolations, the long-term collagen per cell results differed. 
Similar trends were observed for both isolations for the three stretching regimens; 
however, the magnitude of the improvement in collagen content was substantially 
lower. The additional isolation exhibited much higher basal collagen production, 
suggesting that the collagen synthesis pathway was already “saturated.” A thorough 
investigation of this variability between isolations is outside the scope of this work but 
may provide insight into some of the largely unexplored portions of the collagen 
production pathway.  
In summary, the transient nature of ERK1/2 and p38 phosphorylation was 
characterized in a fibrin-based engineered tissue model (Chapter 2), and the results were 
used to develop intermittent and incremental strain amplitude cyclic stretching 
regimens. While ERK1/2 was repeatedly activated in both regimens, incremental 
stretching resulted in a greater increase in collagen per cell, indicating that ERK1/2 
45 
phosphorylation alone is not a sufficient predictor of this long-term outcome of interest. 
The data suggest that an incremental stretching regimen with small, frequent increments 
is most beneficial for collagen production in this system and motivate the use of a 
similar regimen in our engineered cardiovascular tissue bioreactor systems. 
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3.5. Figures 
 
Figure 3-1. 
Schematics of strain versus time for 48 hour (a) constant amplitude, (b) intermittent, 
and (c) incremental cyclic stretching regimens. 0.5Hz frequency and 15% duty cycle 
were used in all regimens. 
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Figure 3-2. 
 (a) Collagen I,α1 and (b) collagen III,α1 mRNA levels at 48 hours in constant 
amplitude, intermittent, and incrementally stretched samples expressed relative to static 
control. GAPDH was used as the housekeeping gene. No significant differences were 
observed between groups (one-way ANOVA, n=5 per group, pooled from two 
experimental repeats). 
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Figure 3-3. 
Total collagen per cell at harvest for static, constant amplitude, intermittent, and 
incremental regimens after 2 weeks. Data were pooled from two experimental repeats 
and normalized to respective static controls.  $=different from static control (p<0.01), 
#=different from all other stretched treatment groups (p<0.01) using one-way ANOVA 
with Tukey post hoc test (n=6 per group). 
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Figure 3-4. 
Total collagen per cell at harvest for three intermittent regimens after 3 weeks. Data are 
normalized to continuously stretched controls. No significant differences were observed 
between groups (one-way ANOVA with n=3 per group). 
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Chapter 4. Computational Model of Solid Sleeve Cyclic Distension 
Bioreactor for Large Diameter Tubular Tissue Constructs 
 
4.1. Introduction 
 A variety of systems for mechanically conditioning cells, tissues, and even 
whole organs are commercially available.63-65 While these systems offer some 
advantages, including tight control of mechanical stimulation and continuous 
monitoring, they are often expensive and lack functional versatility. In our laboratory, a 
custom bioreactor was designed for culturing the large diameter tubular constructs used 
to create our tissue engineered heart valves. This system is a modification of the pulsed 
flow-stretch bioreactor, which was previously used successfully to create small 
diameter vascular grafts with sufficient burst pressure for implantation in preclinical 
small and large animal models.35 The design is simple: after several weeks of static 
culture, the tubular tissue is placed over a latex support sleeve, and the sleeve is secured 
to two custom ULTEM end pieces with cable ties (Figure 4-1a). The sleeve, tissue, and 
end pieces are placed into a culture jar, and a reciprocating syringe pump is used to 
cyclically pump medium into the lumen of the latex tube, thus cyclically stretching the 
tissue (Figure 4-1b,c). The latex support sleeve is much stiffer than the engineered 
tissue, so the strain of the latex-tissue composite is dictated by the latex properties 
rather than by the changing properties of the developing tissue. Although the small 
diameter graft pulsed flow-stretch bioreactor did not require a latex support sleeve, this 
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component is necessary to ensure uniform strain and prevent tissue damage for the 
larger diameter (>16 mm) tissue tubes. 
 While the bioreactor does not permit feedback control of the applied strain, by 
calibrating the system for a range of syringe stroke volumes, predictable and consistent 
strain amplitudes can be applied to the large diameter tubular constructs. Benefits of this 
simple system include ease of set up, operation, and sterilization. In addition, as the 
materials for the bioreactor are relatively inexpensive, it is feasible to change parts and 
add features as needed. With this in mind, it is desirable to develop a computational 
model for the bioreactor, so the effects of changing a geometrical parameter or 
component on the applied strain amplitude can be investigated prior to purchasing or 
machining a new part. A fluid structure interaction (FSI) model of this bioreactor was 
developed using COMSOL Multiphysics® utilizing an arbitrary Lagrangian-Eulerian 
method approach with the goal of accurately predicting the strain amplitude for a given 
stroke volume in this bioreactor system. The model was validated by comparison with 
experimentally measured strain amplitudes over a range of relevant pump stroke 
volumes. 
  
4.2. Methods 
4.2.1. Model Geometry 
The finite element method software, COMSOL Multiphysics (version 5, 
COMSOL, Inc.), was used to create a two-dimensional axisymmetric model of the large 
diameter tubular construct bioreactor. The geometry is shown in Figure 4-2. The upper 
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and lower ULTEM end pieces, latex support sleeve, and walls of the culture jar wall 
were all included in the model. The tubular tissue was not included in the model, as the 
applied strain was dictated primarily by the latex sleeve with the tissue stiffness being 
less than 1/10th that of the latex. The geometric parameters are given in Table 4-1. 
 
Table 4-1. Geometric parameters for the solid sleeve bioreactor model 
Parameter Description Value Source 
L Axial length of latex (between end pieces) 37.96 mm Measured 
Ri Inner radius of latex 9.50 mm Measured 
Th Thickness of latex 0.80 mm Measured 
Rinlet Inlet radius 1.00 mm Measured 
Routlet Outlet radius 0.35 mm Measured 
Hend Height of end cap 12.77 mm Measured 
Hjar Height of jar 80 mm Measured 
Rjar Radius of jar 30 mm Measured 
 
4.2.2. Material and fluid properties 
Three materials were defined in the model: water at 20°C for the fluid domain, 
ULTEM for the two custom end pieces, and latex for the support sleeve. During 
bioreactor culture, the fluid domain typically consists of DMEM culture medium with 
10% fetal bovine serum; however, the density and viscosity are nearly the same for 
culture medium and water,66 so water was used to allow for easy visualization during 
experimental validation. As the experimental validation was performed on the bench 
top, the room temperature properties of water were used instead of properties at the 
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37°C incubator temperature. The necessary parameters for water,67 ULTEM,68 and 
latex69 were determined from the literature. As the elastic modulus and Poisson’s ratio 
of the latex were not specified by the manufacturer, these properties were measured 
experimentally by directed research student Alex Weston using a Bose Electroforce® 
3200 tensile testing apparatus. The material and fluid properties are given below in 
Table 4-2,a-c. Both ULTEM and latex were treated as isotropic linear elastic materials. 
 
Table 4-2a: Fluid Properties (Water at 20°C) 
Parameter Value Source 
Density 998.2 kg/m3 [67] 
Dynamic Viscosity 1.00X10-3 kg/m*s [67] 
 
Table 4-2b. ULTEM Properties 
Parameter Value Source 
Elastic modulus 3600 MPa [68] 
Poisson’s Ratio 0.3 [68] 
Density 1270 kg/m3 [68] 
 
Table 4-2c: Latex properties 
Parameter Value Source 
Elastic modulus 1.2 MPa Measured by Alex Weston for directed research, 
Fall 2014 
Poisson’s Ratio 0.35 Measured by Alex Weston for directed research, 
Fall 2014 
Density 970 kg/m3 [69] 
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4.2.3. Governing Equations and Boundary Conditions 
4.2.3.1. Fluid domain 
In the fluid domain, the fluid flow was governed by the incompressible Navier-
Stokes equations in a moving coordinate system, neglecting contributions of gravity or 
any other volume forces:  
  − ∇ ∙ − + μ ∇ + ∇
 +   ∙ ∇  = 0 
∇ ∙  = 0 
where ρ is the fluid density, ufluid is the fluid velocity, P is the pressure, I is the identity 
matrix, and µ  is the dynamic viscosity of the fluid. Axial symmetry was applied along 
the Z-axis (Figure 4-3, red line). All jar surfaces (Figure 4-3, blue lines) were treated as 
walls and the no-slip boundary condition was enforced. The top fluid surface was 
assigned an “open boundary” condition on which atmospheric pressure was applied. 
The opening at the top of the upper ULTEM end piece was defined as an inlet. Two 
different inlet boundary conditions were studied: cyclic normal inlet velocity and cyclic 
inlet pressure. The cyclic normal velocity boundary condition was defined by the 
piecewise function, 
 =  sin"#$ , 0 <  ≤ 1	* 
 = 0, 1	* <  ≤ 2	* 
where t is time and vmax is inflow velocity, calculated from the stroke volume of the 
syringe pump. The cyclic inlet pressure boundary condition was similarly defined by 
the piecewise function, 
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 =  sin"#$ , 0 <  ≤ 1	* 
 = 0, 1	* <  ≤ 2	* 
where Pmax is the maximum inlet pressure, as measured by an in-line pressure 
transducer in the experimental validation. Continuous second derivative smoothing was 
used to achieve a gradual transition between the two halves of the functions. All 
boundaries between the fluid and latex or ULTEM were treated as moving walls, in 
which the fluid velocity must match the deformation rate (time derivative of 
displacement) of the solid boundary.  
 
4.2.3.2. Solid domains 
The stresses and structural deformations in the solid domains (latex and 
ULTEM) were determined by solving an equation for equilibrium, a constitutive 
equation relating stress and strain, and a kinematic equation relating displacements and 
strain: 
,-./ 
012
0 − 3 ∙ 4 = 56 
4 = 178"5$595
:
 
9 = ;: = 
= = 12 >312 + "312$
 + "312$312? 
where ρsolid is the density of the solid material, usolid is the displacement of the solid 
domain, σ is the Cauchy stress, Fv is the body force per unit volume, F is the 
deformation gradient tensor, S is the second Piola-Kirchoff stress tensor, C is the 
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elasticity tensor, and = is the Green strain tensor. All materials were isotropic and linear 
elastic. As in the fluid domain, a boundary of axial symmetry was enforced along the Z-
axis (Figure 4-3, red line). The top edge of the upper ULTEM end piece and latex 
sleeve (Figure 4-3, purple line) were constrained by a fixed constraint boundary 
condition, imposing zero displacement in both R and Z directions. The interfaces 
between the latex sleeve and the ULTEM end pieces were treated as if they were 
attached along their entire lengths, with continuity enforced across the boundaries 
between the materials. On all boundaries between the fluid domain and the latex or 
ULTEM, a boundary load was applied, representing the contributions of both pressure 
and viscous forces from the fluid. This load was given by: 
5@-A/BC = −D ∙ E−F + G ∇ + ∇:H 
where ufluid is the fluid velocity field, P is the pressure, I is the identity matrix, µ  is the 
dynamic viscosity for the fluid, and n is the normal vector to the boundary.  
 
4.2.4. Moving Mesh and Solver Configuration 
The governing equations for the fluid domain were solved on a moving 
deformed mesh, with mesh deformations computed using hyperelastic smoothing. The 
mesh deformation was prescribed to be zero in both R and Z directions along all 
exterior boundaries of the fluid domain. The mesh in the solid domains moved 
according to the deformations of the ULTEM and latex. A free triangular mesh was 
used and was refined until minimal change in the solution was detected. The system of 
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equations was solved using a PARDISO direct solver with a relative tolerance of 10-4 
and a fully-coupled approach. 
  
4.2.5. Experimental Validation of COMSOL Model 
 In order to validate the COMSOL model, experiments were carried out in which 
the pump stroke volume, inlet pressure, and resulting strain were monitored for a 
bioreactor with identical geometry to the model. Briefly, a latex tube was secured over 
the custom end pieces and placed in a glass container with flat sides to prevent optical 
distortion. Rather than cell culture medium, which is red in color, water was used 
during the validation experiments to allow better measurement of the latex deformation. 
A laser micrometer (Mitutoyo) was used to monitor the changing diameter of the latex 
through the jar during bioreactor operation. The micrometer beam was focused at the 
midpoint between the two ULTEM end pieces. Water was cyclically injected into the 
lumen of the latex tube, and the changing tube diameter was monitored. An in-line 
pressure transducer (Harvard Instruments) recorded the pressure at the inlet to the top 
ULTEM end piece. This procedure was repeated for three different latex sleeves at four 
different pump stroke volumes. The baseline and maximum diameter were recorded for 
each case, and the diametral strain, εD, was calculated as 
IJ = KLMN		/NONBO.	/NONB . 
The maximum diametral strain and peak pressure were averaged over six cyclic 
distension cycles for each trial.  
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4.3. Results 
 
4.3.1.FSI Model Results 
 The FSI model was able to be solved for a range of reasonable inlet flows and 
pressures as well as perturbations to the bioreactor geometry. The deformation, von 
Mises stress, and velocity field predicted by the model for a pressure amplitude of 4.7 
kPa are shown at t = 0.2, 0.5, 0.8, 1.2, and 1.6 seconds. (Figure 4-4a-e) Figure 4-4f 
shows the radial displacement of the latex at the midpoint between the two ULTEM end 
pieces as a function of time. As the pressure was increased toward Pmax, the stress and 
deformation of the latex sleeve also increased with maximum radial displacement 
occurring just after the peak in the inlet pressure at t = 0.52 seconds. Figure 4-4g shows 
the radial displacement of the latex at t = 0.2, 0.5, and 0.8 seconds as a function of Z-
coordinate along the length of the latex sleeve. The predicted radial displacement was 
uniform along the majority of the latex sleeve, tapering to zero at the attachment points 
to the end pieces. 
 
4.3.2. Model Validation: Inlet Velocity Boundary Condition 
 The FSI model predictions were compared to experimental results using the inlet 
velocity boundary condition for four different pump stroke volumes. Experimental 
strain measurements were recorded for four different stroke volumes, and the COMSOL 
model was run for the inlet velocities corresponding to each stroke volume. For both the 
COMSOL model and the experiment, the maximum strain in the latex (measured at the 
59 
midpoint between the ULTEM end pieces) is plotted versus stroke volume (Figure 4-5). 
At the lower stroke volumes there was good agreement between the model and the 
experimental results; however, as the stroke volume was increased, the disparity 
between the model predications and experimentally measured strains increased. This 
was most pronounced at the 3.3 ml stroke volume with the model predicting a strain that 
was 33% higher than the average measured strain at that stroke volume. 
 
4.3.3. Model Validation: Inlet Pressure Boundary Condition 
 Similarly, the experimentally measured and model predicted strains were 
compared with the cyclic inlet pressure boundary condition for the same four different 
pump stroke volumes. An in-line pressure transducer recorded the peak inlet pressure 
for each of the four stroke volumes, and this pressure was set as Pmax for the inlet 
pressure boundary condition. The measured and predicted peak strains are plotted 
versus the peak inlet pressure (Figure 4-6). Good agreement exists between the 
experimental result and model predictions at all four stroke volumes. 
 
4.4. Discussion 
 An FSI model of the solid sleeve bioreactor used for culturing large diameter 
tissue constructs has been developed in COMSOL using an arbitrary Lagrangian-
Eulerian method. A time-dependent inflow or pressure was set at the bioreactor inlet, 
and the incompressible Navier-Stokes equations in a moving coordinate system and 
linear elastic structural deformations were solved for the fluid and solid domains, 
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respectively. The model was stable for a wide range of inlet conditions and geometries, 
encompassing the useful configurations for tubular construct culture. Two different inlet 
boundary conditions were studied: a cyclic inlet velocity, which was calculated from the 
pump stroke volume, and a cyclic inlet pressure, measured by an in-line pressure 
transducer. There was good quantitative agreement in maximum strain between the 
model predictions and experimental result for all stroke volumes when the inlet pressure 
boundary condition was used. When the inlet velocity boundary condition was used, the 
model predictions agreed with the experimental results at the smaller stroke volumes 
but over-estimated the strain for stroke volumes larger than 1.3 ml. This disparity 
increased with increasing stroke volume. 
 With the solver configuration, meshing scheme, and boundary conditions used 
in this study, the FSI model was able to be solved for a wide range of physically 
reasonable inlet conditions, geometries, and material parameters. Both cyclic inlet 
pressure and cyclic inlet velocity produced cyclic radial distension of the latex support 
sleeve, and this distension was fairly uniform along the entire length of the sleeve 
(Figure 4-4g) as was observed visually in the physical bioreactor set-up. Prior to 
experimental validation, an intuitive evaluation was performed during which parameters 
were varied and the outcomes were compared. Diametral strain increased with 
increasing inlet velocity and pressure amplitudes and decreased with an increase in the 
elastic modulus of the latex sleeve or outlet radius. As the model was found to behave 
in an intuitively reasonable manner, experimental validation was carried out for 
quantitative evaluation. 
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 The primary goal in developing this model was to be able to input the pump 
stroke volume or corresponding inlet velocity amplitude and have the model accurately 
predict the strain amplitude in the latex support sleeve and thus the strain applied to a 
tissue construct. However, it was clear from the comparison between the FSI model 
predictions and experimental outcome that the model was not able to accurately predict 
the measured latex strain at all stroke volumes when the inlet velocity boundary 
condition was used (Figure 4-5). In an ideal system, all of the fluid injected by the 
reciprocating syringe pump must exit the lumen of the latex through the outlet in the 
lower end piece. However, in the real system the connection between the latex sleeve 
and the end pieces is not a perfect seal, and leaks through the cable tie attachment points 
do occur, especially at higher stroke volumes. This explains why the over-prediction of 
the model became worse with increasing stroke volume when the inlet velocity 
boundary condition was used. As the stroke volume and therefore the internal pressure 
increased, the leakage became more severe, and the idealized model failed to capture 
the behavior of the system. 
 In order to get around the issue of leakage, a cyclic pressure inlet boundary 
condition was employed using the inlet pressure amplitude that was recorded during 
experimental validation. In terms of the utility of the model, setting the inlet pressure is 
not as attractive as setting the inlet velocity because the pressure is not directly 
controllable in the experimental set-up, while the inlet velocity can be controlled 
directly by adjusting the pump stroke volume. However, in terms of validating the 
model, setting the inlet pressure based on the in-line measurement was useful as it 
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accounted for the leaking that occurred in the physical system. Any leakage of fluid 
from the lumen of the latex should have decreased this in-line pressure reading. As 
expected, when the inlet pressure boundary condition was employed, there was 
excellent agreement between the measured and predicted strain amplitudes at all stroke 
volumes (Figure 2-6). This further suggested that the previous disparities between the 
experimental results and model predictions at high stroke volumes were due to leakage, 
which resulted in lower than predicted internal pressures. 
 While the utility of the FSI model is limited by the leakage in the physical 
system, this study did serve to illuminate the substantial effect of leakage on the applied 
strain in the system and motivates improvement in the sealing mechanism if higher 
strain amplitudes are desired. If a better seal can be accomplished, the value of the 
model as a predictive tool will certainly be increased. Although the FSI model with the 
inlet velocity boundary condition cannot be used to accurately predict the outcome as 
geometrical and material parameters are varied at all stroke volumes, it is still a useful 
tool for making a semi-quantitative assessment of effects, particularly for bioreactor 
configurations with maximum internal pressures below 7 kPa. 
 In the present work, an FSI model of the solid sleeve bioreactor used to culture 
engineered tissue tubes for heart valve applications was developed in COMSOL. The 
model was validated experimentally, and it was determined that when a cyclic pressure 
inlet boundary condition was used the model-predicted and experimentally measured 
strain amplitudes were in excellent agreement. However, when the more physically 
relevant inlet velocity boundary condition was employed, the model failed to accurately 
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predict the outcome for large stroke volumes due to system leakage. While this 
discrepancy at high stroke volumes limits the utility of the FSI model, the model may 
still be a valuable tool for exploring different bioreactor geometries and materials at low 
stroke volumes.  
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4.5. Figures 
 
 
Figure 4-1. 
 (a) Image of the solid sleeve bioreactor consisting of a latex support sleeve, ULTEM 
end pieces, tubular tissue, and culture jar. (b) and (c) images of the reciprocating 
syringe pump used to cyclically inject medium into the lumen of the latex tube. 
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Figure 4-2. 
2D axisymmetric bioreactor geometry with geometric parameters specified in Table 4-
1. Adapted from A. Weston. 
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Figure 4-3. 
Boundary conditions for COMSOL model. The vertical red line is the axis of rotational 
symmetry (left edge of fluid domain), blue lines indicate a wall boundary condition 
(bottom and right edges of fluid domain), and the purple line indicates a fixed constraint 
boundary condition on the solid domains (labeled with arrow). 
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Figure 4-4. 
COMSOL model results: (a-e) Deformation, von Mises stress, and arrows indicating relative 
velocity magnitude and direction at t = 0.2, 0.5, 0.8, 1.2, and 1.6 seconds for an inlet pressure 
amplitude of 4.7 kPa. Arrows are scaled in each image to better show the velocity field at each 
time point. (f) Radial displacement at the midpoint of the latex sleeve as a function of time and 
(g) radial displacement plotted versus z-coordinate along the latex sleeve at t = 0.2 (blue, 
bottom), 0.5 (green, top), 0.8 (red, middle) seconds. 
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Figure 4-5. 
Experimentally measured (open circle) and model predicted (line) maximum diametral 
strain versus pump stroke volume. At each stroke volume the mean and range of the 
three experimental repeats are plotted. 
 
Figure 4-6. 
Experimentally measured (open circle) and model predicted (line) maximum diametral 
strain versus peak inlet pressure. At each pressure the mean and range of the three 
experimental repeats are plotted. 
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Chapter 5. Design and Implementation of a Porated Sleeve Bioreactor 
for Enhanced Nutrient Transport in Large Diameter Tubular 
Constructs 
 
5.1. Introduction 
While there are many advantages to using fibrin as a scaffold for engineered 
cardiovascular tissue, one major drawback is fibrin’s initially low strength and stiffness. 
As mentioned previously, a challenge that must be overcome when working with fibrin 
scaffolds is achieving sufficient strength and stiffness to withstand physiological 
loading. To reduce the cost of culturing a fibrin-based tissue-engineered heart valve 
(TEHV) for several months, it is desirable to achieve these properties as quickly as 
possible. In addition to optimizing the cyclic stretching regimen to increase cellular 
collagen production, another approach to reduce the culture time of fibrin-based tissues 
is to improve nutrient transport through the thickness of the tissue. In cardiovascular 
tissue engineering applications, relying on diffusion alone for transport of oxygen, 
growth factors, and other key nutrients often limits the thickness of viable, cellular 
tissue.70 This transport limitation increases in severity as the cells within the engineered 
tissue proliferate and produce a dense extracellular matrix.  
A variety of bioreactor systems have been developed that apply ablumenal71 or 
lumenal72,73 flow in an attempt to overcome this limitation and improve transport during 
the culture of engineered cardiovascular tissues. In addition, transmural flow, which 
provides forced convection of culture medium through the thickness of the tissue, has 
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shown promise as a means to increase cell viability and metabolism in the interior of 
thick tissues. Kitagawa et al. observed increased uniformity and proliferation of 
fibroblasts in a 2 mm thick synthetic polymer graft under radial perfusion.74 Similarly, 
perfusion has been shown to increase the viability and metabolic activity of 
cardiomyoctes at the center of an engineered tissue 1.5 mm in thickness.75 
It has been shown previously in our lab that a combination of lumenal, 
ablumenal and transmural flow and cyclic stretching was beneficial for small diameter 
(2-4 mm) tubular constructs, increasing both collagen content and burst pressure.35 
When scaling up this bioreactor to culture large diameter (16-22 mm) constructs, it was 
necessary to include a latex support sleeve to ensure uniform strain throughout the 
length of the tubular tissue and prevent necking. Cyclic stretching with a latex support 
sleeve has been used successfully to strengthen fibrin-based tissue tubes;31,42 however, 
when the tissue is placed over a solid latex sleeve, only the ablumenal tissue surface is 
in contact with the medium, and both lumenal medium contact and transmural flow are 
not permitted. In the large diameter tubular constructs, the medium contacting surface 
shows more rapid remodeling of fibrin into collagen, likely due to increased nutrient 
concenrations.31 The elastic support sleeve is required for the cyclic stretching aspect of 
bioreactor culture; however, it is desirable to redesign this sleeve to recover the 
beneficial effects of lumenal and transmural flow. 
In this study a bioreactor with a porated latex support sleeve was designed to 
culture large diameter tissue tubes for TEHV applications, and a computational fluid 
dynamics (CFD) model was developed using COMSOL Multiphysics® to predict the 
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flow velocity field in and around the tissue. It was hypothesized that culture in the 
porated sleeve bioreactor would accelerate remodeling of the fibrin gel scaffold, 
particularly near the lumenal surface, due to increased nutrient diffusion permitted by 
lumenal medium contact as well as the introduction of convective nutrient transport 
resulting from the transmural flow and possible stimulatory effects of lumenal and 
interstitial shear stress. Acceleration of tissue remodeling will reduce the culture time 
required for the tubular constructs to reach sufficient strength and stiffness for use as 
TEHVs. 
 
5.2. Methods 
 
5.2.1. Cell Culture 
Neonatal human dermal fibroblasts (Invitrogen) were expanded in 50:50 
DMEM:F12 (Lonza) with 15% fetal bovine serum (Hyclone), 100 U/ml penicillin, and 
100 µg/ml streptomycin. Passage 7 fibroblasts were harvested at confluence for use in 
tissue constructs. 
 
5.2.2. Construct Fabrication and Culture 
Tubular constructs were formed by casting a fibrin gel with entrapped dermal 
fibroblasts around a cylindrical mold. The mold consisted of a 22 mm diameter glass 
mandrel that was secured within a polycarbonate outer shell by tight fitting rubber 
stoppers. Prior to casting, the mandrels and outer shells were immersed in a solution of 
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5% Pluronic F-127 in distilled water for 2 to 4 hours and allowed to air dry. A well-
mixed solution of fibroblasts, bovine fibrinogen (Sigma), bovine thrombin (Sigma), 20 
mM HEPES-buffered saline, DMEM+HEPES, and CaCl2 was injected into the negative 
space between the mandrel and outer casing and allowed to gel for 10 minutes at 20°C 
and an additional 30 minutes at 37°C. Final gel concentrations were 1 million/ml 
fibroblasts, 4 mg/ml fibrinogen, 0.8 U/ml thrombin, and 5 mM CaCl2. After gelation the 
tubular constructs were ejected from the outer casing into jars containing 250 ml 
construct culture medium (DMEM with 10% fetal bovine serum, 1% 
antibiotic/antimycotic, 2 µg/ml insulin, and 50 µg/ml ascorbic acid). All constructs were 
housed in a standard cell culture incubator at 37°C. After five days to allow initial gel 
compaction, jars were placed on a rocker and rocked at a frequency of approximately 
0.5 Hz. Medium was replaced three times per week.  
 
5.2.3. Porated Sleeve Fabrication 
Porated sleeves were created by laser cutting holes into latex tubing (Primeline 
Industries) using an Epilog laser (UMN CSE Machine Shop). The latex sleeve was 
placed over a mandrel and rotated such that either 8 or 16 columns of holes were cut 
around the circumference of the tube, as shown in Figure 5-1a. Pores were cut in the 
central 2.5 cm of the latex sleeve, based on the predicted axial length of the tissue tubes 
following cell-induced fibrin gel compaction during the initial static incubation. Pore 
diameter of 200 µm and axial spacing of 2.6 mm were used. 
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5.2.4. Bioreactor Conditioning 
After three weeks of static culture to allow for gel compaction, tubular 
constructs were cyclically stretched in a custom built bioreactor.31 Constructs were slid 
off their mandrels and placed over distensible sleeves which were either porated, as 
described above, or solid latex. Each tissue and supporting sleeve was fixed to ULTEM 
end pieces with cable ties and placed in a jar containing 200 ml of construct culture 
medium (Fig 5-1b). Cyclic distension was achieved by pulsatile flow of medium 
delivered by a reciprocating syringe pump. The pump injected medium through a 3-way 
valve into the lumen of the latex sleeve, and the back pressure produced by a small 
constriction point on the lower end piece caused the latex and tissue to cyclically 
distend.  The syringe was refilled by drawing medium from the reservoir surrounding 
the tissue.  
Constructs were conditioned for one or two weeks with cyclic distension at a 
frequency of 0.5 Hz and amplitude increasing incrementally over approximately 1-3% 
(1 week) or 1-6% (2 week) with increments of 1% every 2 days. In addition to the solid 
sleeve control, a second control group was included in which the lower end piece was 
removed from the porated sleeve bioreactor preventing pressurization of the tube lumen. 
This configuration provided pulsatile flow of medium through the lumen of the porated 
sleeve at the same volumetric injection rate but with no measureable distension (peak 
lumenal pressure less than 150 Pa). 
Calibration of tube distension was performed using a laser micrometer 
(Mitutoyo) to measure the circumferential strain. Calibration was performed for solid 
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and porated latex sleeves with constructs that had been cultured statically for three 
weeks then placed over the sleeves. The culture jar was replaced with a square glass jar 
containing phosphate-buffered saline during calibration to minimize optical distortion. 
The laser micrometer was used to measure the circumferential strain of the latex-tissue 
composite as the stroke volume of the pump was varied. 
 
5.2.5. Mechanical Testing  
Uniaxial tensile tests were performed using an Instron testing system on strips 
cut from the tubular constructs in the circumferential direction (~2.5 mm by 12 mm). 
The tissue strips were placed in compressive grips and submerged in phosphate buffered 
saline throughout the test. Tissues were pre-stressed with a load of 0.008 N and six 
preconditioning cycles (0-10% strain) were performed. Tissues were stretched to failure 
at a rate of 3 mm/min as the force from the load cell was recorded.  The engineering 
stress was calculated by dividing the force by the initial cross-sectional area of the 
tissue strip and the true strain was calculated from the instantaneous and initial lengths 
of the strip. The ultimate tensile strength (UTS) was the maximum stress achieved 
before failure, and the tangent modulus was calculated by performing regression on the 
linear portion of the stress-strain curve. 
 
5.2.6. Histology and Immunostaining 
Tissue strips cut from tubular constructs both circumferentially and axially were 
fixed in 4% paraformaldehyde, embedded in optimal cutting temperature compound 
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(OCT, Tissue-Tek), and frozen. For constructs cultured in the porated sleeve 
bioreactors, axial strips were taken both from regions along a column of pores and 
regions between columns of pores. 9 µm sections were stained with Lillie’s trichrome 
and picrosirius red stains. Sections were also stained for collagen I, α1 (Novus, NB600-
408). Samples were blocked in 5% normal donkey serum, incubated in primary 
antibody at a concentration of 1 µg/ml, and stained with Cy3-conjugated anti-rabbit 
secondary antibody (Jackson Immunoresearch). Hoechst 33342 (Invitrogen, H3570) 
was used to counterstain nuclei. 
The cell distribution was quantified using a custom MATLAB® script.76 
Briefly, the user identifies the lumenal and ablumenal tissue surfaces, and the script 
determines the distance of the centroid of each cell from the lumenal surface. This 
quantification was performed on 4X images of Hoechst-stained axial sections. For each 
section a series of 4X images was pieced together to span the entire length of the axial 
section.  
 
5.2.7. Collagen and Cellularity Quantification 
Collagen content was quantified using a hydroxyproline assay with a conversion 
factor of 7.46 mg of collagen for 1 mg 4-hydroxyproline.56 A modified Hoescht assay 
was used to determine cellularity.57 
 
5.2.8. Measurement of Sleeve-Tissue Gap and Computational Fluid Dynamics (CFD) 
Model 
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In order to predict the flow field around and through the tissue tube, the 
dynamics of the tissue and sleeve distension were studied, and a basic CFD model was 
developed using COMSOL Multiphyics®. As the sleeve and tissue were distended by 
the pulsatile influx of medium, a gap formed between the tissue and the sleeve, and 
medium was able to flow both along the lumenal surface of the tissue as well as through 
the tissue thickness (transmural flow). The width of this gap was able to be 
approximated by monitoring the distension of the tissue/sleeve composite versus the 
sleeve alone under the same lumenal pressure amplitude using a laser micrometer. The 
peaks of the distension versus time profiles were aligned, and the gap width, W, was 
approximated at a set of discrete time points during a cycle as 
P"$ = 	QO"$ − Q,"$ − 2ℎ , 
where Dt was the outer diameter of the sleeve/tissue composite, Ds was the outer 
diameter of the sleeve alone, and h was the thickness of the tissue. As the strains 
utilized were small, it was assumed that the tissue thickness was constant throughout the 
distension cycle. 
 A CFD model was developed for the tissue at the onset of bioreactor culture 
using the measured tissue properties, lumenal pressure waveform, and gap width 
dynamics for the initial strain amplitude of 1%. The lumenal pressure and gap width 
were both set manually for different points in the cycle, and the flow of medium 
through and around the tissue was solved at steady state for each pressure/gap width 
pair. There was no physical coupling between fluid flow and tissue deformation 
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included in this basic model. Both the maximum and time-averaged pressure/gap width 
pairs are considered here.  
An approximation of the full porated sleeve bioreactor geometry neglecting 
curvature was used (Fig. 5-2a), in which an axial segment including one column of 
pores bounded by symmetry conditions on the lateral faces defined the total domain. As 
the diameter of the sleeve and tissue were much greater than the thicknesses, this was a 
reasonable approximation of the full geometry and decreased the required time for 
computation. The model included discrete inlets (representing the pores in the sleeve), a 
gap domain in which fluid was able to flow freely, and a tissue domain represented by a 
homogeneous, isotropic porous material. The gap width was assumed to be constant in 
the axial direction, as the experimentally measured gap width was fairly uniform, 
decreasing slightly (<10%) at the top and bottom tissue edges. The parameters used in 
this model are included in Table 5-1. 
 
Parameter Description Value Source 
L ½ axial length of porated 
sleeve/tissue 
13.7 mm Measured 
Dpore Pore diameter 200 µm Measured 
H Tissue thickness 1 mm Measured 
d Axial pore spacing 2.6 mm Measured 
W Gap width 0.4 mm, maximum  
0.25 mm, time averaged 
Measured 
P Lumenal pressure 500 Pa (peak) 
318 Pa (time averaged) 
Measured 
 
Table 5.1: Input parameters for porated sleeve bioreactor model 
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 The COMSOL Multiphysics® module for free and porous media flow was used 
to seamlessly couple flow in the gap region with flow through the porous tissue. At each 
pore in the latex sleeve, an inlet boundary condition was specified using the measured 
lumenal pressure, and on all exterior surfaces (Figure 5-2b, purple lines) an outlet 
pressure of 0 Pa was specified. Along the solid portions of the latex sleeve (Figure 5-2b, 
green lines) a no-slip boundary condition was utilized. Fluid flow in the gap region was 
governed by the steady-state Navier-Stokes equations: 
−∇ ∙ >− + G"∇ + "∇$$? + "$ ∙ ∇ = 0 
∇ ∙  = 0 
and flow in the porous material was governed by the Brinkman equations: 
−∇ ∙ − + GI "∇ + "∇$
$ + GS  = 0 
∇ ∙  = 0 
where u is the velocity, P is the pressure, I is the identity matrix, µ  is the dynamic 
viscosity of the fluid, ρ is the fluid density,  and ε and κ are the porosity and 
permeability of the porous material, respectively. Continuity of stress and continuity of 
velocity were enforced across the interface between the gap and tissue domains. The 
properties of water at 37°C were used for the fluid, and previously measured values for 
the permeability and porosity of fibrin-based tissue constructs were used for the porous 
material. These properties are given in Table 5-2.  
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Parameter Value Source 
Density 992 kg/m3 [67] 
Dynamic Viscosity 6.9X10-4 kg/m*s [67] 
Tissue Permeability 10-15 m2 [77] 
Tissue Porosity 0.4 Measured by Muaz 
Nik Rushdi, directed 
research Spring 2012 
Table 5-2: Fluid and tissue properties used in porated sleeve bioreactor model 
 
A free tetrahedral mesh was used for both domains and was refined until 
minimal change in the solution was detected. The system of equations was solved using 
a generalized minimal residual (GMRES) iterative solver with relative tolerance of 10-6. 
 
5.2.9. Statistics 
All figures show mean ± standard deviation with at least n = 3 per group. 
Significance was determined using Student’s t-test for two groups and one-way 
ANOVA with a Tukey-Kramer post hoc test for more than two groups with p<0.05 
reported as significant. All experiments were repeated at least twice and porated sleeve 
data were normalized to solid sleeve control values for each experiment to account for 
variation between castings. 
 
5.3. Results 
 
5.3.1. Lumenal collagen deposition after one week of bioreactor conditioning 
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Tubular constructs were cyclically stretched for one week with either solid 
support sleeves (control) or porated sleeves with eight columns of pores around the 
circumference of the sleeve. Lumenal collagen deposition was not observed in samples 
cultured on solid latex sleeves (Figure 5-3a,c). Regions of lumenal collagen deposition 
were observed in the tissues conditioned on the porated sleeves (Figure 5-3b,d), as 
indicated by the green straining in Lillie’s trichrome on circumferential sections. 
However, this thin collagen layer was not present across the entire lumenal surface of 
the tissue, and appeared to be concentrated in patches that were 300-500 µm in width as 
viewed in circumferential sections. There were no differences in cellularity, collagen 
per cell, UTS, or modulus between the porated sleeve samples and the solid sleeve 
controls (Figure 5-3e-h). 
 
5.3.2. Localization of collagen layer to porated regions 
In order to investigate the regions of lumenal collagen deposition observed in 
the porated sleeve samples, a two-week experiment was performed in which tissues 
were cyclically stretched on porated sleeves with the same pore array (8 circumferential 
columns of pores). At harvest, axial strips were taken between columns of pores (Figure 
5-4a, red box) and along columns of pores (Figure 5-4a, blue box). Lumenal collagen 
deposition was not observed in sections that were taken from areas between columns of 
pores (Figure 5-4b,d). However, along a column of pores, a layer containing cells and 
collagen was present on the lumenal tissue surface (Figure 5-4c,e).  
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5.3.3. Lumenal remodeling increased with increased pore density and culture duration 
In an attempt to increase the uniformity of lumenal collagen deposition, sleeves 
with 16 columns of pores were fabricated, and tissues were cultured for two weeks on 
these porated sleeves alongside solid sleeve controls. Figure 5-5 shows trichrome-
stained axial and circumferential sections from tissues cyclically stretched on solid and 
porated sleeves as well as porated sleeve controls lacking the bottom end piece. All 
porated sleeve sections shown in Figure 5-5 were taken along rows or columns of pores. 
A highly cellular region was present on the lumenal surface of the cyclically stretched 
porated sleeve samples (Figure 5-5b,e,h,k), and a thin layer of collagen was present in 
this region. Serial sectioning revealed that 1 mm wide axial strips with high cell density 
were centered on each pore column. The cell nuclei in this layer appeared elongated in 
the circumferential sections (Figure 5-5h) and punctate in the axial sections (Figure 5-
5k) indicating that the cells were aligned circumferentially. In the solid sleeve controls 
“dead zones,” areas with few cells and little remodeling, were present on the lumenal 
surface as indicated by the black arrows in Figure 5-5a,d,j. In the porated sleeve control 
samples with the lower end piece removed, there was no evidence of lumenal collagen 
layer (Figure 5-5c,f,i,l). These controls had a thickness of 0.90±0.09 mm and were 
thinner than both the cyclically stretched porated sleeve samples (1.36±0.06 mm) and 
solid sleeve controls (1.24±0.11 mm). 
Sections stained for type I collagen (Figure 5-6) clearly showed that the lumenal 
layer in the cyclically stretched porated sleeve samples consisted of densely packed 
cells surrounded by collagen. Picrosirius red staining also highlighted the lumenal layer 
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of collagen present in tissues cyclically stretched on these porated sleeves (Figure 5-7). 
This layer was not present in solid sleeve control samples. Despite these apparent 
localized differences, in terms of bulk properties there were no differences in cellularity, 
collagen per cell, UTS, or modulus between the porated sleeve samples and the solid 
sleeve controls (Figure 5-7e-h). 
 
5.3.4. Porated sleeve culture increases cell density near lumenal surface 
The distribution of cells was quantified in sections from tissues cyclically 
stretched for two weeks on solid sleeves or porated sleeves with 16 columns of pores. 
For samples cultured on porated sleeves, the cell distribution was quantified for axial 
sections taken along columns of pores and between columns of pores. The dense cell 
layer present in the porated sleeve samples was ignored in this count, and the “lumenal 
surface” was defined just inside this layer. Cell nuclei were counted in three different 
zones, 25-100 µm, 100-175 µm, and 175-250 µm from the surface, and data are 
reported as cells/4x image. Nuclei within 25 µm of the surface were not counted to 
avoid including cells that were part of the dense lumenal layer present in the porated 
sleeve samples. In sections taken along a column of pores, the cell density was 
increased in the 25-100 µm region compared to solid sleeve controls (Fig. 5-8). In 
contrast, in sections taken between columns of pores there was no increase in cell 
density compared to solid sleeve controls. There were no differences in cell density 
among any of the groups in the regions that were more distant from the lumenal surface 
(>100 µm). 
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5.3.5. CFD model predictions for flow field 
 For both the time-averaged and maximum inlet pressure/gap width conditions, 
the CFD model predicted flow of medium that was primarily lumenal, with less than 
0.01% of the flow volume entering the tissue. Figure 5-9 shows the CFD model 
predictions for the time-averaged boundary pressure/width condition. The normal 
velocity at the lumenal surface (Fig. 5-9a) of the tissue was highest directly across the 
gap from the discrete pores, and away from the pores the normal velocity was several 
orders of magnitude smaller. The transmural velocity decreased sharply within ~300 µm 
upon entering the tissue (Fig. 5-9b) with much of the flow recirculating back into the 
gap as indicated by the negative sign of the normal velocity in regions surrounding each 
pore (Fig 5-9a). The transmural velocity magnitude and flow streamlines are shown in 
Figure 5-9c, clearly highlighting the flow pattern. The lumenal shear stress (Fig. 5-9d) 
was also elevated within ~0.5 mm of each discrete pore.  
While peak transmural flow velocity approached 150 µm/s, the average velocity 
over the entire tissue volume was 0.3 µm/s for both maximum and time-averaged 
lumenal pressures. This volume-averaged transmural velocity translates to a Peclet 
number (Pe) of 0.2 for dissolved oxygen and ~2 for growth factors such as epidermal 
growth factor, using diffusion coefficients measured in fibrin gels.78,79 After 3 weeks of 
static culture, our tissue tubes were substantially denser at ~100 mg/ml protein than a 
typical 3 mg/ml fibrin gel, so the above Peclet numbers provide a conservative estimate.  
The average lumenal shear stress was computed for both the tissue as a whole 
and the region where improved remodeling was observed, approximated by a 
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rectangular prism centered on the column of pores with a width of 1 mm and depth of 
100 µm into the tissue. The shear stress magnitude imposed on the cells by the 
interstitial flow was also estimated based on the computed interstitial velocity using the 
theory of Wang and Tarbell.80 These values are summarized in Table 5-3.  
CFD model prediction Time-averaged 
lumenal pressure 
Maximum 
lumenal pressure 
Average transmural (radial) 
velocity – whole tissue 
0.3 µm/s 0.3 µm/s 
Average interstitial shear stress 
magnitude – whole tissue 
0.06 dyn/cm2 0.06 dyne/cm2 
Average interstitial shear stress 
magnitude – improved region 
0.2 dyn/cm2 0.4 dyn/cm2 
Average lumenal shear stress 
magnitude – whole tissue 
8 dyn/cm2 14 dyn/cm2 
Average lumenal shear stress 
magnitude – improved region 
13 dyn/cm2 32 dyn/cm2 
Table 5-3. CFD model predictions for flow in and around tissue tube 
 
Averaged over the full tissue volume, the time-averaged lumenal and interstitial 
shear stresses were 8 dyn/cm2 and 0.06 dyn/cm2, respectively. In the improved region, 
shear stress magnitudes were approximately twice the volume-averaged values with 
magnitudes of 13 dyn/cm2 and 0.2 dyn/cm2 for the lumenal and interstitial shear 
stresses, respectively. 
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5.4. Discussion 
In the previously employed bioreactor used to culture tissue tubes for heart valve 
applications,31 lumenal and transmural flow were prevented by the presence of a solid 
support sleeve used to ensure uniform tissue strains. While the solid sleeve bioreactor 
applied well-controlled cyclic strain to the tissue, it was desirable to combine this 
mechanical stimulation with the enhanced nutrient transport and possible shear stress 
stimulation that lumenal and transmural flow provide.35,66,72-74,77,81 After one week of 
bioreactor culture on porated support sleeves, there were no differences in the bulk 
properties of the tissues compared to solid sleeve controls; however, there was evidence 
of lumenal remodeling of the fibrin gel scaffold into cell-produced collagen in the 
proximity of the pores (Fig. 5-3b,d). Due to the relatively low pore density of the sleeve 
with just 8 columns of pores and the short culture duration, it was not surprising that 
differences were not observed in the overall tissue composition, strength, or stiffness. 
The regions of lumenal remodeling were small compared to the overall tissue volume; 
therefore, they did not substantially influence the tissue properties. In order to examine 
the location of the regions of lumenal remodeling, a two-week experiment was 
performed in which tissues were cultured on the same porated sleeves, and axial 
sections were taken from areas both between and along columns of pores (Fig. 5-4). The 
localization of lumenal remodeling to the columns of pores in the support sleeve 
verified that the observed effects were a direct consequence of the pores, and confirmed 
the hypothesized benefit of lumenal and transmural flow. 
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 In an effort to improve the uniformity of remodeling across the lumenal surface 
of the tissue, the density of pores in the support sleeve was doubled and two-week 
experiments were conducted. A dense layer of circumferentially oriented cells 
surrounded by collagen was present along columns of pores, extending at least 1 mm in 
width. This layer was similar in appearance to the ablumenal surface of the tissue, 
which was in contact with the recirculating medium (Figures 5-5-5-7). The collagen-
rich layer at the ablumenal surface was ~3 times as thick as the lumenal layer; however, 
the ablumenal surface of the tissue was in contact with culture medium for the 3 weeks 
of static culture before the tissues were mounted into the bioreactor while the lumenal 
surface was in contact with the glass mandrel. The lumenal remodeling was not 
observed in any of the solid sleeve control samples nor in the non-distending porated 
sleeve controls with the lower end piece removed. It was noted that there were “dead 
zones” with few cells and very little collagen production at the lumenal surface of many 
of the solid sleeve control samples. It is hypothesized that these dead zones were a 
result of insufficient nutrient transport though the tissue or related shear stimulation. 
In samples cyclically stretched on porated sleeves, the cell density within 100 
µm of the lumenal surface along a column of pores was double that of the solid sleeve 
controls. This indicated that there was enhanced cell survival and/or proliferation in this 
region. While in the solid sleeve samples and between columns of pores the cell density 
was lower at the lumenal surface and reached a plateau around 175-250 µm, along pore 
columns the cells were distributed uniformly throughout the tissue tube wall (Figure 5-
8). In a perfusion bioreactor, Kitagawa et al. found that by applying transmural flow to 
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synthetic polymer scaffolds seeded with NIH/3T3 cells they were able to achieve a 
uniform distribution of live cells throughout the thickness of the engineered tissue 
compared to samples cultured without flow.74 Perfusion-enhanced cell viability, 
proliferation, and metabolic activity have also been observed for a variety of other cell 
types.75,81-83  
 As lumenal medium contact, lumenal flow, and transmural flow occurred 
simultaneously with porated sleeves in this bioreactor, the mechanism behind the 
increased remodeling and cellularity is unclear. While the contact of culture medium 
certainly enhanced transport at the lumenal surface via diffusion, there was also the 
possibility of convective transport due to transmural flow through the porous tissue as 
well as shear-induced cell stimulation due to lumenal and transmural flow. A CFD 
model was developed to predict the flow field around and through tissue tubes in the 
porated sleeve bioreactor. The model was developed using the tissue properties and 
pump settings at the onset of bioreactor culture, and while additional work must be done 
to investigate transmural flow velocities as the tissue matures, the model predicted the 
transmural flow magnitude and lumenal flow at early time points.  
In line with experimental observations, the CFD model predicted that the effects 
of the porated sleeve were localized to regions near the discrete pores in the sleeve (Fig. 
5-9). Averaged over the entire tissue, the transmural flow velocity was only 0.3 µm/s, 
which is substantially smaller than the transmural flow velocity (21 µm/s) in the pulsed 
flow-stretch bioreactor employed to culture small diameter vascular grafts without an 
elastic support sleeve.35 Although the volume-averaged transmural velocity was small, 
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the corresponding Peclet numbers of ~0.2-2 for key nutrients suggest that both diffusion 
and transmural convection may have contributed to the increased cellularity and 
remodeling observed along columns of pores, at least at early time points. In addition, 
the transmural flow velocity was substantially higher near the discrete pores (Fig. 5-9c), 
and convective transport was likely dominant in these regions. 
In the region of increased cellularity and remodeling around the pores, both the 
lumenal and interstitial shear stresses were elevated. Shear-induced alterations in gene 
expression and motility have been observed for fibroblasts in both 2D and 3D culture, 
although the effects have not been studied as extensively as for endothelial cells.84 
Increased proliferation and differentiation of dermal fibroblasts in a perfused collagen 
gel has been reported with interstitial shear stresses ranging from 0.15 to 0.33 
dyn/cm2,81 which are similar in magnitude to the predicted interstitial shear stresses in 
the regions of improved remodeling in our system (0.2-0.4 dyn/cm2). 
While differences were visible in the histological sections, there were no 
measured differences in the overall cellularity, collagen per cell, UTS, or modulus 
between the solid sleeve and porated samples. Although this appears to conflict with the 
finding of increased cell and collagen density near the lumenal surface in the porated 
sleeve samples, it should be noted that this region comprised only a small fraction of the 
tissue (~2.5%). In addition, the bulk properties of the tissue were assessed for 
circumferential strips spanning three columns of pores, so it is likely that the localized 
differences were masked when averaged over the large volume. 
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There were several limitations to the basic CFD model, including the 
assumption of constant gap width around the circumference of the bioreactor. As the 
tissue did not slide off the sleeve during culture, the gap width must have been variable 
around the circumference, with points of contact between the tissue and sleeve between 
columns of pores. This variable gap width would generate asymmetry in the lumenal 
flow with increased flow along columns of pores where the gap was widest. In addition, 
fluid-structure interaction was not included in the current model, as the available 
pressure and gap width data made it possible to obtain predictions for the flow field in a 
less computationally intensive manner. While a full fluid-structure interaction model 
may be able to predict the gap width asymmetry and more accurately describe the flow 
field, the development of this complex model is unnecessary to approximate the flow 
field and associated shear stresses. 
  These results suggest that with optimization of the porated sleeve design and 
extended culture duration, the porated sleeve bioreactor can be used to increase cell 
density and accelerate fibrin remodeling into a collagenous matrix at the lumenal 
surface of large diameter engineered tissue tubes. It is clear that increased pore density 
is required to achieve uniform remodeling, as currently the remodeling was limited to a 
quarter of the lumenal surface. As pore density is increased, care must be taken to avoid 
applying detrimental magnitudes of lumenal or transmural flow, as high flow rates may 
damage the tissue or wash out newly synthesized matrix components.77 Based on the 
CFD model predictions, the current transmural flow velocities are at least an order of 
magnitude lower than those employed in our sleeve-less small diameter vascular graft 
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bioreactor,35 suggesting that a moderate increase in transmural flow will not have 
damaging effects. 
In the present work, a porated sleeve bioreactor was developed to culture large 
diameter engineered tissue tubes for tubular heart valve applications with the ultimate 
goals of accelerating tissue formation and reducing the required culture duration. 
Preliminary studies with this bioreactor support this approach, highlighting the 
beneficial effects of combined lumenal medium contact and lumenal and transmural 
flow on cellularity and collagen deposition. While the enhanced remodeling was 
localized to regions near pores in the elastic support sleeve, these short-term results 
motivate long-term implementation of this bioreactor and optimization of the porated 
sleeve design for improved tissue uniformity.  
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5.5. Figures 
 
 
Figure 5-1. 
(a) Porated latex sleeve with 16 columns of pores and (b) porated sleeve bioreactor with 
a 22 mm diameter tissue tube mounted over the central porated region. 
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Figure 5-2. 
(a) Three-dimensional schematic of model geometry showing the porated sleeve, fluid domain, 
and tissue domain. The symmetry faces are indicated with an asterisk. (b) Cross-section of 
model geometry showing boundary conditions and geometric parameters. No-slip (green lines, 
left edge of geometry) was enforced along the solid portions of the sleeve, an outlet pressure of 
0 Pa was applied on exterior surfaces of the domain (purple lines, bottom and right edges of 
geometry), and symmetry was enforced (red line, top edge of geometry) on the top surface to 
generate the full axial length of the gap/tissue. The inlet pressure was set at the five pores in the 
sleeve. 
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Figure 5-3. 
1-week study results. 10x (a,b) and 20x (c,d) images of trichrome-stained circumferential sections 
from tissues cyclically stretched on solid sleeves (left) and porated sleeves (right) for 1 week. The 
lumenal surface of the tissue is on the right. Red staining indicates non-collagenous protein, green 
indicates collagen, and nuclei are stained dark purple/black. All scale bars are 200 µm. (e) Cell 
number per volume, (f) collagen per cell, (g) UTS, and (h) modulus for solid sleeve and porated 
sleeve samples. Data represent two experimental repeats, and all values are normalized to solid 
sleeve controls (n=3-4 per group). 
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Figure 5-4. 
Localization of collagen deposition to columns of pores. (a) Locations of axial sections 
taken from areas between columns of pores (red box, left) and along a column of pores 
(blue box, right) after two weeks of bioreactor culture. 10x trichrome stained sections of 
areas (b,d) between columns of pores and (c,e) along columns of pores. The lumenal 
surface is on the right in all images, and scale bars are 200 µm. 
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Figure 5-5. 
Trichrome-stained 4x (a,b,c) and 10x (g,h,i) circumferential sections and 4x (d,e,f) and 
10x (j,k,l) axial sections of tissues cultured on solid sleeves (left), porated sleeves 
(center), or porated sleeves with the lower bioreactor end piece removed (right) for two 
weeks. Black arrows indicate “dead zones” present on the lumenal surface of solid 
sleeve control tissues. All porated sleeve sections shown here were taken along columns 
of pores. The lumenal surface of the tissue is on the right. All scale bars are 200 µm. 
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Figure 5-6. 
4x (a,b) and 10x (e,f) circumferential sections and 4x (c,d) and 10x (g,h) axial sections stained 
for type I collagen (red) and counterstained with Hoechst dye (blue). Tissues were cyclically 
stretched on solid sleeves (left) or porated sleeves with 16 columns of pores (right) for two 
weeks. All porated sleeve sections shown here were taken along columns of pores. The lumenal 
surface of the tissue is on the right. All scale bars are 200 µm. 
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Figure 5-7. 
4x images of picrosirius red-stained circumferential sections from tissues cyclically stretched on 
solid sleeves (a,c) and porated sleeves with 16 columns of pores (b,d) for two weeks. In all images 
the lumenal surface of the tissue is on the right. White arrows in (a) and (c) indicate the lumenal 
surface of the tissue. All scale bars are 200 µm. (e) Cell number per volume, (f) collagen per cell, (g) 
UTS, and (h) modulus for solid sleeve and porated sleeve samples. Data represent three 
experimental repeats, and all values are normalized to solid sleeve controls (n=3 per group). 
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Figure 5-8. 
Cell count per 4X image in zones 25-100 µm, 100-175 µm, and 175-250 µm from the 
lumenal tissue surface for samples cyclically stretched on solid sleeves or porated 
sleeves (both along and between columns of pores) for two weeks. Horizontal bars 
indicate differences in cell number (p<0.05) using one-way ANOVA with Tukey-
Kramer post hoc test (n=3-4 per group) 
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Figure 5-9. 
CFD model results for the time-averaged pressure/gap width condition. (a) A plot of the normal velocity 
(m/s) at the lumenal tissue surface (en-face view). (b) The transmural (radial) velocity is plotted versus 
distance into the tissue along a horizontal line centered at each of the five pores with pore 1 being closest 
to the outlet boundary and pore 5 nearest the symmetry surface. (c) A side view of the transmural (radial 
velocity) magnitude (m/s) and velocity streamlines through the thickness of the tissue. A magnified view 
of the flow near a pore is indicated by the purple box. (d) A plot of the shear stress magnitude (dyn/cm2) 
at the lumenal tissue surface (en-face view). A magnified view of the shear stress near a pore is indicated 
by the red box. All surface plots (a,b,d) are oriented such that the bottom pore is the one closest to the gap 
outlet and the top pore is nearest the symmetry surface. The vertical white line indicates the boundary of 
the 1 mm by 100 µm “improved” region. 
100 
Chapter 6. Conclusions and Future Directions 
 
6.1. Major Contributions 
The present work has contributed substantially to the fields of 
mechanotransduction and cardiovascular tissue engineering. These contributions were 
communicated through oral and poster presentations at both local and national 
conferences, and three manuscripts have been published or are in preparation. A 
synopsis of the major contributions of this work to the field is included in the following 
sections. 
 
6.1.1. Overcoming adaptation to cyclic stretching: ERK1/2 and p38 activation 
 The basic research utilizing the Flexcell® tension system described in Chapter 2 
provided insight into the interaction between the ERK1/2 and p38 pathways in 
cyclically stretched fibroblasts. While it has been documented that cells adapt to 
constant amplitude cyclic stretching, the underlying cell signaling producing this 
phenomenon had not been well characterized prior to the present work. The cells' six 
hour refractory period before possible ERK1/2 reactivation coincided with the return of 
p38 phosphorylation to basal levels, suggesting that the transient activation of p38 
serves to keep ERK1/2 activation in check. In addition, it was determined that both an 
additional onset of cyclic stretching as well as small increments (>1%) in strain 
amplitude can fully reactivate ERK1/2 once p38 activation has subsided. As ERK1/2 
activation has been shown to be required for cyclic-stretching induced collagen 
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deposition, this research provided the basis for the development of optimized cyclic 
stretching regimens for tissues where high mechanical strength and stiffness are 
required. 
 
6.1.2. ERK1/2 activation alone is not sufficient to induce increased collagen deposition 
 Chapter 3 describes the long-term application of regimens selected based on 
ERK1/2 phosphorylation dynamics with the goal of increasing collagen deposition by 
fibroblasts in a fibrin gel. It was determined that while both intermittent and 
incrementally increasing strain amplitude cyclic stretching regimens reactivated 
ERK1/2, only incremental cyclic stretching increased cellular collagen deposition 
compared to continuously stretched controls. This indicates that contrary to prior 
hypotheses, ERK1/2 activation alone is not a sufficient predictor of final collagen 
content. In our fibrin gel system, an incremental regimen with daily increments in strain 
amplitude of 1% was able to increase collagen per cell 34% compared to controls 
stretched with constant amplitude after only two weeks, and this improvement may 
shorten the required culture time in our engineered cardiovascular tissues. 
 
6.1.3. Development of a fluid-structure interaction model for solid sleeve tubular tissue 
bioreactor 
 The development of a fluid-structure interaction model for the currently 
employed tubular tissue bioreactor is described in Chapter 4. The COMSOL 
Multiphysics model predicts the fluid flow and structural deformation of the solid 
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support sleeve given the pump stroke volume or inlet pressure and the geometry and 
properties of the support sleeve. This model showed excellent agreement with 
experimental measurements at low stroke volumes. It is expected that the model will 
serve as a useful tool for exploring alterations in bioreactor geometry and materials 
prior to purchasing or machining a new part or material. In addition, the model provides 
the framework to ensure that adequate cell culture medium mixing occurs as parameters 
or materials are altered. 
 
6.1.4. Design of a porated sleeve bioreactor improved lumenal remodeling in large 
diameter tissue tubes 
 A porated sleeve bioreactor was designed to enhance nutrient transport in large 
diameter engineered tissue tubes for heart valve applications. Proof-of-concept studies 
using this new bioreactor design demonstrated that bioreactor culture utilizing a porated 
support sleeve resulted in the presence of a dense layer of cells and collagen at the 
lumenal surface as well as increased cell density extending 100 µm into the tissue from 
this layer. In addition to the experimental bioreactor implementation, a COMSOL 
model was developed to predict the flow velocity field in and around the tissue. While 
medium contact certainly enhanced nutrient diffusion at the lumenal surface, model 
predictions suggested that localized convective effects and shear stimulation may have 
contributed to the increased lumenal remodeling observed along columns of pores. 
These studies highlight the beneficial effects of lumenal and transmural flow and 
motivate long term implementation of this system as well as optimization of porated 
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sleeve parameters. Furthermore, this bioreactor configuration may find additional 
applications in construct decellularization and/or recellularization prior to construct 
implantation. 
 
6.2. Future Directions 
 
6.2.1. Further Characterization of Cyclic Stretching-Induced Collagen Production 
Pathway 
 Studies of ERK1/2 and p38 signaling, collagen transcription, and collagen 
deposition provided considerable insight into the response of fibroblasts to cyclic 
stretching in a three-dimensional engineered tissue environment highlighting the 
complexity of the cell signaling response and downstream effects. It was determined 
that ERK1/2 signaling alone is not a sufficient indicator of collagen production. In 
addition, preliminary investigations into lot-to-lot variability presented in Appendix A 
suggest that similar ERK1/2 activation in two different lots of fibroblasts may result in 
different collagen deposition outcomes. 
 As the intermediate steps between ERK1/2 activation and collagen deposition 
are largely uncharacterized,41 further study of the cyclic stretching-induced collagen 
production pathway is necessary to better understand the system dynamics and predict 
the long-term collagen deposition outcome. While ERK1/2 signaling and p38 inhibition 
have been implicated as key players in the collagen production pathway, complex 
crosstalk occurs between the mitogen activated protein kinase (MAPK) cascades, and it 
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is important to consider individual cascades within the greater context of the full MAPK 
network.85,86 Additionally, now that the methods are in place to characterize MAPK 
phosphorylation with the Nanopro Immunoassay system, it is possible to obtain detailed 
information about isoform specific phosphorylation rather than simply considering each 
cascade as an on/off switch. It is possible that by studying the MAPK network as a 
whole, differences in in the “reactivation” due to intermittent versus incremental cyclic 
stretching and/or lot-to-lot variation in signaling dynamics will become apparent.  
 In addition to a detailed study of the MAPK network, there is still much work to 
be done in characterizing the downstream effects of cyclic stretching. Study of 
intermediate steps in the collagen production pathway such as transcription factor 
activation86 and binding86,87 and gene promoter activity43,87 can help to provide a 
valuable link between MAPK signaling and gene expression. Finally, while the bulk of 
the current research has focused on collagen production, it is equally important to 
consider the effects of cyclic stretching on matrix metalloproteinase (MMP) profiles, 
collagen degradation, and collagen maturation.60-62 Future work investigating the 
comprehensive effects of cyclic stretching on cell signaling as well as matrix 
deposition, degradation, and remodeling may aid in the further optimization of 
bioreactor conditioning regimens for accelerated tissue formation. 
 
6.2.2. Optimization of Porated Sleeve Parameters  
 Culture in the porated sleeve bioreactor resulted in the presence of a dense 
lumenal layer of cells and cell-produced collagen. However, this layer was not present 
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across the entire lumenal surface of the tissue but was localized along lines of discrete 
pores in the sleeve. When pore density was doubled from 8 to 16 columns of pores 
around the sleeve circumference, there were still areas in the porated sleeve samples 
that were lacking this lumenal cell layer and remodeling. Future work focusing on the 
porated sleeve design is required in order to achieve uniform remodeling of the entire 
engineered tissue tube, and iterative optimization will be required to assess the tissue 
properties and uniformity as the pore array is altered. While it is expected that further 
increasing pore density will result in more uniform remodeling of the lumenal surface, 
negative effects such as medium pooling and tissue damage may be associated with the 
increased flow. These trade-offs will have to be balanced, and it is expected that the 
COMSOL model will be a valuable tool for predicting the flow through and around the 
tissue as sleeve parameters are changed.  
 It may be possible to fabricate a porated sleeve that promotes uniform lumenal 
tissue remodeling using the current method of laser cutting discrete pores into solid 
latex tubing. However, the pore diameter and array options are limited by the power and 
precision of the laser cutting system, and as increased pore densities are sought, it may 
be necessary to seek out an alternative method for producing the porated support 
sleeves. With the increasing prevalence of 3D printing and electrospinning 
technologies, it may be possible to fabricate elastic sleeves with more uniform porosity 
for use in the bioreactor system. As several elastic materials are available for use with 
3D printers and electrospinners, it may now be feasible to print or spin a porous, elastic 
structure for use as a support sleeve.88-90 These technologies show promise as affordable 
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and flexible options for optimizing sleeve design for accelerated, uniform tissue 
remodeling. 
 
 6.2.3 Fluid Structure Interaction Model of Porated Sleeve Bioreactor 
 In Chapter 5 a CFD model describing flow through and around the tissue in the 
porated sleeve bioreactor was presented. This model was useful for predicting the 
lumenal and transmural flow velocities; however, many simplifications were made in 
the creation of this model. The cyclic motion of the sleeve and tissue were ignored, and 
the tissue was treated as a stationary porous object rather than a deforming poroelastic 
material. In order to better understand the applied strain and flow patterns, a full FSI 
model must be developed. Implementing arbitrary Lagrangian Eulerian techniques as 
presented in Chapter 4 for the solid sleeve bioreactor is less straightforward when a 
poroelastic material is included in the model.  
At present, COMSOL does not have built-in functionality allowing coupling of 
the Navier-Stokes equations employed in the free flow domain with the Biot 
poroelasticity formulation used for the tissue domain. However, there has been 
extensive study of the appropriate coupling conditions for these two domains, and it 
may be possible to implement these constraints in a custom designed interface 
condition. Badia et al. provide a comprehensive overview of the conditions and methods 
used to couple these two domains, and they present a well-posed problem with 
enforcement of continuity of velocities and stresses at the interface.91 Calo et al. 
employed a simplified Biot formulation written in terms of the pore pressure and 
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structural velocity only; however, the use of this simplified form requires the 
application of artificial boundary conditions at the interface.92 
Future work should consider how best to implement proper interface conditions 
in COMSOL or if an alternate software package is better equipped to solve this 
problem. In addition to developing the computational framework for this system, a 
thorough study of the properties of the developing engineered tissue will add increased 
accuracy to the model. The tissue thickness, permeability, porosity, and poroelastic 
constitutive constants change as the tissue matures, and the time dependent tissue 
properties must be characterized for the model to be relevant throughout the course of 
bioreactor culture.  The development of a fully coupled FSI model of the porated sleeve 
bioreactor with well-defined parameters is highly desirable as it will permit us to better 
predict the strain magnitude and flow velocities experienced by the developing tissue 
construct. In addition, it may be possible to couple the fluid flow results with kinetic 
data to predict concentrations of key nutrients within the tissue or investigate use of a 
similar system for the detergent decellularization of tubular constructs.31    
 
6.2.4. Long-term Application of Optimized Cyclic Stretching in Porated Sleeve 
Bioreactor  
 Optimized cyclic stretching and enhanced nutrient transport have been 
investigated in parallel for accelerating the remodeling of the fibrin gel scaffold into 
cell-produced collagen. The next step in improving bioreactor culture for the large 
diameter engineered tissue tubes would be to implement this optimized cyclic stretching 
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(1% daily increments in strain amplitude) in the porated sleeve bioreactor for long term 
culture. While this follows the logical progression of iterative bioreactor improvement, 
in practice this combination poses several challenges. Unlike the previously employed 
solid sleeve bioreactor, in the porated sleeve bioreactor the applied strain is affected to 
some extent by the properties of the developing tissue. Variability in tissue properties 
has been observed both between castings and even between tissues within the same 
casting. In the solid sleeve system, this variability is not a major issue, because the 
strain is largely dictated by the stiffness of the latex sleeve. In contrast, in the porated 
sleeve system, some sort of feedback control will be required to apply precise strain 
amplitudes (less than 1% variation between samples). This may be as simple as 
periodically measuring the strain with the laser micrometer and adjusting the pump 
accordingly; although automated control may be desired in future systems.  
The current porated sleeve bioreactor studies have been limited to two weeks in 
duration and 6% strain amplitude. As the durations of future experiments are extended 
toward the standard culture periods of four to five weeks, additional studies must be 
performed to investigate the effects of lumenal and transmural flow in more mature 
tissues subjected to larger strain amplitudes. As high transmural flow velocities may 
have negative consequences on collagen deposition,74.77 care must be taken to balance 
the desired strain amplitude with a flow velocity that is conducive to tissue formation. 
However, with these practical challenges overcome, it is hypothesized that 
implementing optimized cyclic stretching in a bioreactor system that allows for lumenal 
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medium contact and transmural flow will further accelerate collagen production in the 
engineered tissues. 
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Appendix A. Comparison of Collagen Production in Two Lots of 
Dermal Fibroblasts 
 
A.1. Motivation 
 Chapters 1 and 2 present data for a single lot of neonatal human dermal 
fibroblasts (lot #0000232777, Lonza). During the course of these experiments, a second 
lot of neonatal human dermal fibroblasts was purchased (lot #1165554, Invitrogen), and 
this lot was used alongside the original fibroblasts. These lots are referenced using the 
last three digits of the lot numbers (777 and 554) throughout this section. Almost 
immediately, differences were noted in the collagen deposition by these two lots of 
cells, both in the Flexcell disc format as well as qualitatively in the larger tubular valve 
constructs. In order to provide insight into these differences, a side-by-side comparison 
of both the basal (static) collagen production as well as the cyclic stretching-induced 
response was performed in the Flexcell system format. All procedures were performed 
according to the methods described in Chapters 1 and 2. 
 
A.2. Comparison of ERK1/2 Activation 
 First, ERK1/2 phosphorylation was measured for both cell lots after 15 minutes 
of 5% constant amplitude cyclic stretching. Cells were entrapped in fibrin gel scaffolds 
as described in Chapters 1 and 2. As shown in Figure A-1, there was increased ERK1/2 
phosphorylation in both cell lots due to cyclic stretching, 3.7-fold and 5.4-fold by the 
777 and 554 cells, respectively. While it appears that the 554 cells achieved higher 
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ERK1/2 activation levels than the 777 cells, additional experiments would be required 
to definitively confirm this difference. After only 15 minutes of cyclic stretching 
ERK1/2 phosphorylation levels are changing rapidly, so this difference may be an 
artifact of the order in which the plates were removed from the system and harvested. 
What is known is that ERK1/2 was activated by cyclic stretching on the same order of 
magnitude in both cell lots. 
 
A.3. Collagen Deposition by 554 and 777 Fibroblasts 
 Next, collagen deposition by cells from the two lots was compared. Fibrin discs 
with either 777 or 554 cells entrapped were cultured statically for one week, at which 
point they were cyclically stretched with strain amplitude of 5% for one or two weeks. 
Samples that remained in static culture for the additional one or two weeks were 
maintained as static controls. The results of this study are shown in Figure A-2. In static 
culture alone, the 554 cells produced more than twice the amount of collagen at both 
time points. After one week of cyclic stretching (Fig A-2a), both 554 and 777 cells 
exhibited increased collagen deposition per cell; however, the effect was greater for the 
777 cells. After two weeks of cyclic stretching (Fig A-2b), only the 777 cells had 
increased collagen per cell due to cyclic stretching. There was no difference between 
stretched samples and static controls for the 554 cells at this time point.  
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A.4. Discussion and Conclusions  
These results indicated that the 554 cells, which had a higher level of basal 
collagen deposition, were not as responsive to cyclic stretching, in terms of collagen 
deposition. This suggests that the collagen production pathway may have been saturated 
in the 554 cells, and cyclic stretching was unable to stimulate the cells further. 
Interestingly, as discussed above, the ERK1/2 pathway was activated to the same 
extent, if not more, in the 554 cells compared to the 777 cells. Along with the data 
presented in Chapter 2, this further confirmed that ERK1/2 activation alone was not a 
sufficient predictor of final collagen content in our fibrin-based engineered tissues. 
This comparison highlights an interesting phenomenon that had not been 
previously explored in our lab. While the 554 cells were not nearly as responsive to 
cyclic stretching, they produced more collagen in static culture than the cyclically 
stretched 777 cells. While these effects have not been fully characterized in the large 
diameter tubular tissue constructs, it may be that the use of the 554 cells in static culture 
conditions will result in tissues with sufficient mechanical strength and stiffness without 
the need for bioreactor conditioning. However, it should be noted that the present study 
was only concerned with collagen deposition. Other cyclic stretching induced effects 
such as collagen maturation, crosslinking, and alignment may still require cyclic 
stretching even when the 554 cells are used. 
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A.5. Figures 
 
 
Figure A-1. 
Ratio of phosphorylated to total ERK1/2 for 777 and 554 fibroblasts, normalized to 
respective static control. Samples were harvested after 15 minutes of 5% constant 
amplitude cyclic stretching. Horizontal bars indicate difference between static/5% 
stretching groups using Students t-test (n=3 per group). 
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Figure A-2. 
Collagen per cell in constructs after (a) one and (b) two weeks of 5% constant 
amplitude cyclic stretching for 777 and 554 lots of fibroblasts. Horizontal bars indicate 
difference between static/5% stretching groups using Students t-test (n=3 per group). 
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Appendix B. The Effect of Pulse Frequency on Tissue Properties in the 
Porated Sleeve Bioreactor 
 
B.1. Motivation 
 Chapter 5 presented a porated sleeve bioreactor designed to culture large 
diameter fibrin-based tissue tubes for heart valve applications. As discussed, this 
bioreactor accelerated lumenal remodeling in regions within approximately 1 mm of the 
discrete columns of pores. In the previously described studies, the syringe pump 
frequency was set to 0.5 Hz resulting in an influx of medium every two seconds. As this 
lumenal and transmural flow appeared to be beneficial for tissue formation, it was 
hypothesized that it may be possible to further enhance this effect by increasing the 
pump frequency, thus increasing the influx of fresh culture medium at the lumenal 
surface of the tissue. We chose to change the pump frequency rather than the stroke 
volume, because this allowed us to alter the amount of medium delivered to the tissue 
without changing the applied strain amplitude. A study of the effects of two different 
pump frequencies, 0.5 Hz and 0.75 Hz, is presented here. All procedures were 
performed according to the methods described in Chapter 5 using porated support 
sleeves with 16 columns of pores for two weeks of bioreactor culture.  
 
B.2. Effect of Frequency on Collagen and Cellularity  
 After two weeks there were no differences in the cellularity (Figure B-2a) or 
collagen per cell (Figure B-2b) between tissues stimulated with 0.5 Hz or 0.75 Hz pulse 
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frequencies. With the current porated sleeve geometry and culture duration it appeared 
that there was no measurable augmentation in collagen production or cellularity with 
the increased frequency. 
 
B.3. Effect of Frequency of Lumenal Remodeling 
 Histological sections revealed poor fixation in these samples, and the majority of 
the lumenal collagen layer was not well preserved. Prior to this study, all experiments 
had been only one week in duration, and tissue thickness was approximately 0.5-0.6 
mm. In this two week experiment, the harvested tissues were much thicker and more 
remodeled, so it was hypothesized that the volume of fixative was insufficient. The 
volume of 4% paraformaldehyde per sample was increased in subsequent studies 
(including all histological sections shown for two week studies in Chapter 5) from ~2 
mL to ~4 mL to achieve better fixation and avoid loss of the lumenal remodeling layer. 
Additionally, after this study great care was taken to minimize contact with and 
manipulation of the lumenal tissue surface to better preserve this region. 
 Although it was difficult to make out the lumenal layer of collagen and cells, as 
most of this region did not survive fixation and sectioning, it appeared that samples 
stimulated with both frequencies had remnants of lumenal collagen deposition as shown 
by trichrome staining (Figure B-2). 
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B.4. Discussion and Conclusions 
 There were no observable differences in bulk properties or lumenal collagen 
remodeling between samples cultured in the porated sleeve bioreactor with pump 
frequency of 0.5 Hz or 0.75 Hz. An increase in pump frequency did not result in 
increased collagen content or cellularity of the tissue as a whole, and the tissues 
appeared qualitatively similar when visualized with a trichrome stain. It should be noted 
that the sample size for this study was small (n=2 per group), and because it was the 
first attempt at fixing the thicker tissues, it was difficult to compare the poorly fixed 
samples. However, as substantial improvement in tissue formation was not immediately 
apparent at the higher pump frequency, a frequency of 0.5 Hz was utilized in all 
subsequent studies. 
 Pump frequency was selected as the variable parameter in this experiment, as it 
allowed us to increase the influx of culture medium at the lumenal surface without 
changing the applied strain, assuming the sleeve and tissue were able to fully relax back 
to the initial state between each pulse. While this was the case for frequencies less than 
~1 Hz, as pump frequency increased further, the sleeve and tissue tended to balloon out. 
The injected medium did not have sufficient time to flow out of the pores and end cap 
outlet before another pulse of medium arrived. This is obviously not desirable and limits 
the maximum frequency that can be applied in this system without altering the 
geometry of the ULTEM end piece. In addition, cycling at a higher frequency took a 
toll on the plastic syringes used to inject the medium, causing them to break daily rather 
than lasting the two day period between media changes. 
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 By changing the pump frequency rather than the stroke volume, we were able to 
apply the same strain amplitude to all of the tissues. Chapters 1 and 2 highlight the 
effects of cyclic strain amplitude on collagen production in engineered tissues; however, 
all of these studies were performed at a single frequency (0.5 Hz), and it is unknown 
what effect the changing cyclic strain frequency may have on the fibroblasts in our 
system. Isenberg et al. found no effect of stretch frequency on the mechanical properties 
of vascular grafts consisting of smooth muscle cells in a collagen gel scaffold, although 
the pump duty cycle (held constant in the present work) did appear to have an effect.93 
 Although there was no apparent difference between tissues cultured with the two 
different stimulation frequencies in this study, as the porated support sleeve and 
bioreactor culture conditions are further refined, it may be worthwhile to consider the 
effect of pulse frequency once again. This small-scale study considered only two 
frequencies and one porated sleeve geometry, so it does not completely rule out the 
possibility of a frequency effect in porated sleeve bioreactor culture. 
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B.5. Figures 
 
 
 
Figure B-1. 
(a) Cellularity and (b) collagen per cell in samples stimulated at 0.5 and 0.75 Hz 
frequencies (n=2 per group). 
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Figure B-2. 
10X trichrome-stained sections of samples stimulated with (a,c) 0.75 Hz and (b,d) 0.5 
Hz. Remnants of the cell and collagen layer are visible in patches on the lumenal 
surface. The lumenal surface is on the right in all images, and scale bars are 200 µm. 
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Appendix C. Protocols 
 
C.1. Casting Flexcell Plates (3D) 
 
NOTE: This should all be done sterilely, in the hood 
1. Prepare solutions (13 mL per plate, which gives you 1 mL extra) 
 For 1 plate  
Fibrinogen: 2.8 mL lot 021M fibrinogen stock (at 30 mg/mL) + 5.8 mL of 
20mM HEPES 
in saline solution 
 Thrombin: 0.433 mL thrombin stock + 1.7 mL DMEM+HEPES + 32.5 uL 2M 
CaCl2 
 Cells: 2.2 mL of passage 7 nhdfs at 3 million/mL concentration 
2. Mix solutions 4:1:1 by volume (Fibrinogen:Thrombin:Cells) 
 First at cells to fibrinogen and mix well, then add thrombin and mix again 
3. Pipette 2 mL into the center of each well of a Flexcell Tissue Train plate 
4. Quickly tilt the plate around to get the solution to cover the entire foam ring before 
gelation 
5. Let sit in the hood for 6 minutes 
6. Place in incubator for 24 minutes to continue gelation 
7. Add 5 mL of medium (DMEM+10% FBS + 1% anti/anti+2 ug/mL insulin + 50 ug/ml 
ascorbic acid) to each well 
8. Culture in incubator (37°C, 5% CO2, 95% humidity) 
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Equipment and Reagents: 
Name Company Product Number 
Fibrinogen, lot 021M Sigma Lot 021M 
1M HEPES solution Corning 25-060-CI 
0.9% Saline Solution Hospira RL-2099 
Thrombin (25U/mL in 20mM 
HEPES) 
Sigma  
DMEM+HEPES Gibco by Life 
Technologies 
10564-011 
Calcium Chloride Sigma 383147-100G 
Neonatal human dermal 
fibroblasts (Lot 777) 
Lonza Lot #0000232777 
Flexcell Tissue Train Plate, 
circular foam, untreated 
Flexcell International TTCF-4001U 
Incubator Nuaire 5500 
DMEM Gibco by Life 
Technologies 
11995-065 
FBS (fetal bovine serum) Hyclone Lot AXK51176 
Antibiotic/Antimycotic Gibco 15240-062 
Insulin Sigma I9278 
Ascorbic Acid Sigma A5960-100G 
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C.2. Tissue Harvest, Lysis, and Protein Extraction for Western Blot or Nanopro 
Immunoassay 
 
1. Rinse tissue in cold Dulbecco’s phosphate buffered saline (DPBS) 
2. Place tissue in 1.2 mL microcentrifuge tube and snap freeze by submerging in liquid 
nitrogen for >1 min 
3. Store frozen samples at -80°C until you are ready to lyse them and extract the protein. 
4. Prepare lysis buffer on ice (all reagents from Protein Simple) – I use 350 ul per 
flexcell tissue or 100 ul for a 6mm biopsy punch of tissue 
Lysis buffer components: Bicine/CHAPs lysis buffer + 1X Aqueous Inhibitor 
Mix + 1X DMSO inhibitor mix 
5. Add lysis buffer to the microcentrifuge tube with the sample in it – keep on ice 
6. Lyse by sonication – 60% power for 30 seconds 
 Clean the probe between samples with 0.1% Tween 20 in ddH20 
7. Place tubes in the cold room on the end-over-end mixer for 30 minutes 
8. Spin tubes at 13000rpm for 15 minutes at 4°C 
9. Remove supernatant into new microcentrifuge tube, discard the pellet 
10. Store lysates at -80°C.  
11. Quantify protein concentration using BCA Protein Assay Kit 
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Equipment and Reagents: 
Name Company Product Number 
1.2 mL Microcentrifuge 
tubes 
USA Scientific  
Dulbecco’s Phosphate 
Buffered Saline (DPBS) 
Gibco by Life Technologies 14190-144 
Liquid Nitrogen NA NA 
Bicine/CHAPs Buffer Protein Simple CODE: 040-764 
Aqueous Inhibitor Mix 
(25X) 
Protein Simple CODE: 040-482 
DMSO Inhibitor Mix (50X) Protein Simple CODE: 040-510 
125 Volt Sonicator System QSonica LLC Q125 
End-over-end mixer Labnet  
Refrigerated 
microcentrifuge (Alford 
Lab) 
Thermo Scientific  
Tween 20 Sigma Aldrich P1379 
Pierce BCA Protein Assay 
Kit 
Thermo Scientific 23227 
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C.3. Western Blot 
 
Run Gel 
1. Thaw lysates on ice 
2. Prepare 2X Laemmli sample buffer by adding DTT to a final concentration of 50mM 
(100mM) in 2X solution  
3. Dilute lysates to same concentration (according to BCA assay results) and add equal 
volume lysate and Laemmli sample buffer 
4. Boil samples for 5 minutes using the high setting on the heat block 
5. Briefly spin samples to collect in the bottom of the tube 
6. Prepare gels and gel box 
 Remove comb and tape from 4-20% gradient gels 
 Assemble gel box, making sure there is no leakage 
7. Mix 85 mL 10X Tris/Glycine/SDS Buffer with 765 mL water (from distilled water 
tap) 
8. Fill space between gels with 1X SDS buffer and fill outside area in gel box to fill line 
for 2 gels 
9. Starting with dual color protein standard in the first well, use long pipette tips to 
pipette samples into the wells 
10. Run gels at 200V for 1 hour 
Transfer Gel 
1. Mix 80 mL 10X CAPS buffer (recipe below), 80 mL methanol, and 640 mL ddH20 
 CAPS Buffer: 22g CAPS [3-(cyclohexylamino)-1-propane sulfonic acid] in 1 L 
ddH20, 
 pH to 11 
2. Prepare transfer sandwich by soaking all components in 1X CAPS buffer 
 Per gel: 2 pieces of filter paper, 2 sponges, 1 piece of nitrocellulose cut to size 
3. Remove gel from between the two plates by cracking at the 4 arrows 
4. Create “sandwich” in transfer apparatus 
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 1 sponge, 1 filter paper, Gel, Nitrocellulose (roll to get good contact with gel), 1 
filter paper, 1 sponge 
5. Put sandwich in transfer bath with cooling unit and stir bar on stir plate. 
6. Fill with  
7. Run at 75 volts for 1 hour 
Blot for protein of interest (ERK, p38, B-actin) 
1. Remove nitrocellulose from sandwich and place protein side up in dish (I use pipette 
tip box lids) 
2. Incubate in 5% blotting grade blocker+0.1% Tween 20 in PBS for 1 hour at room 
temperature or overnight at 4°C on orbital shaker 
If blotting for p38 or phospho-p38, rinse 3X5 minutes in 1X tris buffered saline 
+ 0.1% Tween 20 (TBST) 
3. Add primary antibody, incubate for 1 hr at room temperature or overnight at 4°C – 
see dilutions below: 
 pERK and tERK (rabbit): 1:2000 in blocking solution 
 p38 and p-p38 (rabbit): 1:1000 in 5% Bovine serum albumin (BSA) in TBST 
 B-actin (mouse): 1:5000 in blocking solution 
4. Rinse 3X5 minutes in TBST 
5. Add secondary antibody corresponding to the primary (mouse or rabbit) 1:2000 (all 
diluted in blocking solution) and incubate for 1 hour at room temperature 
6. Rinse 2X5 minutes in TBST 
7. Rinse 1X5 minutes in TBS 
8. Inclubate in 6 mL ECL solution for 3 minutes 
9. Put in film cassette, expose film, and develop 
To strip and re-blot 
1. Rinse 1X5 minutes in TBS 
2. Rinse 1X15 minutes in Stripping buffer 
3. Rinse 2X5 minutes in TBST 
4. Block, and re-blot 
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Equipment and Reagents: 
Name Company Product Number 
2X Laemmli sample buffer Biorad 161-0737 
DTT (Dithiothreitol) Amresco 0281 
Heat block Fisher Scientific  
Mini centrifuge Costar  
4-20% gradient gels Biorad 456-1096 
Gel box and power supply Biorad  
10X Tris/Glycin/SDS 
Buffer 
Biorad 161-0732 
Precision plus dual color 
protein standard 
Biorad 161-0374 
Gel loading pipette tips Biorad 223-9915 
CAPS Sigma Aldrich C2632-100G 
Transfer sponges Biorad 170-3933 
Filter paper Whatman 1003-917 
Nitrocellulose (Protran) University Stores NBA085C001EA 
Cooling unit Biorad 170-3934 
Blotting grade blocker Biorad 170-6404 
Tween 20 Sigma Aldrich P1379 
Phosphate buffered saline 
(PBS) 
Gibco by Life 
Technologies 
14190-144 
Orbital Shaker Midwest Scientific S2030-LS 
Bovine Serum Albumin 
(BSA) 
Amresco 0175-25G 
Tris buffered saline Thermo Scientific 28358 
Total ERK (p44/42) 
antibody 
Cell Signaling Technology 9102S 
Phospo ERK (p-p44/42) 
antibody 
Cell Signaling Technology 9101S 
Total p38 antibody Cell Signaling Technology 9212S 
Phospho p38 antibody Cell Signaling Technology 9211S 
B-actin antibody (mouse) Sigma Aldrich A5441 
Seconday Rabbit IgG- HRP 
Linked 
GE Healthcare NA934-100UL 
Secondary Mouse IgG – 
HRP Linked 
GE Healthcare NA931-100UL 
ECL: Luminata Classico EMD Millipore WBLUC0100 
Genemate Blue Film, 5X7 University Stores CX24355 
Film Cassette Fisher Scientific FBCA 57 
Restore Plus Stripping 
Buffer 
Thermo Fisher Scientific 46430 
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C.4. Tissue Harvest, Lysis, and RNA Purification for PCR 
 
NOTE: Throughout purification, keep work area clean and wipe down all 
equipiment/surfaces with RNase Away 
1. Harvest tissue and store at 4°C in RNALater in 1.2 mL microcentrifuge tube until 
you’re ready to proceed 
2. Remove RNALater using a micropipette 
3. Add 350ul or 600 ul of RLT Buffer (+DTT) to each sample, following the 
instructions in the RNeasy Plus Mini Kit (see Table 1 for appropriate volume) 
4. Sonicate the tissue in the buffer for 20 seconds at 60% max power 
5. Spin for 3 minutes at 13,000 rpm at room temperature, remove the supernatant and 
use it in the following steps 
6. Complete steps 2-8 in the RNeasy mini kit instructions 
7. Submit sample of purified RNA to BMGC for quantitation on the Nanodrop – see 
current submission instructions at http://www.bmgc.umn.edu/ 
8. Store RNA at -20°C 
Equipment and Reagents: 
Name Company Product Number 
1.2 mL Microcentrifuge 
tubes 
USA Scientific  
RNase Away Spray Sigma Aldrich 83931 
RNAlater Stabilization 
Reagent 
QIAGEN 76104 
RNeasy Plus Mini Kit QIAGEN 74134 
DTT (Dithiothreitol) Amresco 0281 
125 Volt Sonicator System QSonica LLC Q125 
Microcentrifuge (Biofuge 
pico) 
Heraeus  
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C.5. cDNA Synthesis for PCR 
 
NOTE: Throughout synthesis, keep work area clean and wipe down all 
equipiment/surfaces with RNase Away 
1. Combine up to 5 ug total RNA (I try to use a constant amount, based on BMGC 
quantitation), 1uL Random Hexamers, 1uL Annealing Buffer, and RNase/DNAse free 
water to 8 uL total volume in a 0.2 mL PCR tube 
2. Vortex and centrifuge to collect sample in bottom of tube 
3. Heat to 65°C for 5 minutes using thermal cycler 
4. Place on ice for 1 minute 
5. Add 10 uL 2X first strand reaction mix and 2 uL SuperScript III/RNaseOUT Enzyme 
Mix to each tube 
6. Vortex and centrifuge to collect sample in bottom of tube 
7. Using thermal cycler, heat tubes to 25°C for 10 minutes, followed by 50°C for 50 
minutes, then 85°C for 5 minutes 
8. Store cDNA at -20°C. 
Equipment and Reagents: 
Name Company Product Number 
0.2 mL PCR tubes University Stores CX13127 
RNase Away Spray Sigma Aldrich 83931 
SuperScript® III First-
Strand Synthesis SuperMix 
(Contains all components 
that get added to the RNA) 
Life Technologies 18080-400 
Vortex Fisher 12-812 
Mini Centrifuge Costar  
Thermal Cycler (Shen Lab) Thermo  
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C.6. PCR 
 
1. Thaw SYBR Green on ice (and in dark). Thaw primers, and cDNA on bench top 
2. Make a “master mix” for each primer containing (per well) 
 6.25 uL SYBR Green 
 0.0075 uL forward primer 
 0.0075 uL reverse primer 
 ddH20 
3. Pipette 11.5 uL of the appropriate master mix into each well on 384 well PCR plate 
4. Add 1 uL of the appropriate cDNA sample to each well on the PCR plate 
5. Cover with RNAse/DNAse free plate cover, keep on ice and protected from too much 
light 
6. Run on Agilent  
 Cycles: 
  10 minutes at 95°C 
  40 repeats of (30s at 95°C, 1 min at 55°C, 1 min at 72°C) 
  10 minutes at 72°C 
 
Equipment and Reagents: 
Name Company Product Number 
KicQStart SYBR Green Sigma Aldrich KCQS02 
Primers – sequences in 
thesis 
At 100 µM in ddH20 
BMGC  
PCR Plate Life Technologies 4309849 
Optical Plate Cover Agilent Technologies 4360954 
Plate centrifuge (Hall Lab)   
qPCR Machine (Hall Lab) Applied Biosystems 7900HT 
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C.7. Casting 22mm Tubular Constructs 
 
NOTE: This should all be done sterilely, in the hood 
1. Assemble molds – glass mandrels + 2 plungers + Teflon tape 
2. Autoclave molds, outer casings, culture jars, extra Teflon tape, ejector rod, Dacron 
cuffs (2 per VRE) 
3. Soak molds in 5% Pluronic F-127 in water for 1-3 hours 
4. Lay out molds to dry on sterile drape in the hood for ~1 hour 
5. Prepare solutions (36 mL/VRE, may want to make extra if molds are extra long) 
 For 1 VRE  
Fibrinogen: 4.8 mL lot SLBF fibrinogen stock (at 30 mg/mL) + 19.2 mL of 
20mM 
HEPES in saline solution 
 Thrombin: 1.2 mL thrombin stock + 4.8 mL DMEM+HEPES + 90 uL 2M CaCl2 
 Cells: 6 mL of passage 7 nhdfs at 6 million/mL concentration 
6. Assemble molds with Dacron cuffs, and place in outer casings – make sure you have 
a good fit 
7. Mix solutions 4:1:1 by volume (Fibrinogen:Thrombin:Cells) 
 First add cells to fibrinogen and mix well, then add thrombin and mix again 
8. Using a syringe and needle, inject solution into mold, being careful to avoid bubbles 
9. Let sit in the hood for 6 minutes 
10. Place in incubator for 24 minutes to continue gelation (I usually put all molds in 
1000mL beaker and cover with foil to prevent contamination from incubator) 
11. Add 250 mL of medium (DMEM+10% FBS + 1% anti/anti+2 ug/mL insulin + 50 
ug/ml ascorbic acid) to each culture jar 
12. Using Teflon ejector rod, eject VREs 1 at a time from mold into PBS containing 
petri dish and transfer with sterile gloved hands into culture jars 
13. Culture in incubator (37°C, 5% CO2, 95% humidity) 
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Equipment and Reagents: 
Name Company Product Number 
Glass tube mandrels, 0.625” 
inner diameter  
McMaster Carr 8729K47 
Polycarbonate outer casing  McMaster Carr  
Syringe plungers (washed in 
contrex, branson, and water) 
Kendall Monoject  
Teflon tape, Commercial 
Grade, ½” 
TaegaSeal  
Dacron cuffs From St. Jude, special 
arrangement 
 
Pluronic F-127 Sigma P2443-250G 
Sterile drape MediChoice MDRP1001 
Fibrinogen, lot SLBF Sigma Lot SLBF 
1M HEPES solution Corning 25-060-CI 
0.9% Saline Solution Hospira RL-2099 
Thrombin (25U/mL in 20mM 
HEPES) 
Sigma  
DMEM+HEPES Gibco by Life 
Technologies 
10564-011 
Calcium Chloride Sigma 383147-100G 
Neonatal human dermal 
fibroblasts (lot 554) 
Invitrogen Lot #: 1165554 
Sterile 30mL syringe Norm-ject  
Needle, 15G, sterile Monoject  
Culture jar Nalgene  
Ejector rod (12 inch Teflon 
rod, 20mm diameter) 
  
Petri dish Corning 430597 
PBS (Phosphate buffered 
saline) 
Gibco by Life 
Technologies 
14190-144 
Incubator Nuaire 5500 
DMEM Gibco by Life 
Technologies 
11995-065 
FBS (fetal bovine serum) Hyclone Lot AXK51176 
Antibiotic/Antimycotic Gibco 15240-062 
Insulin Sigma I9278 
Ascorbic Acid Sigma A5960-100G 
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C.8. Mounting Tubular Constructs in Biroeactors 
 
NOTE: This should all be done sterilely, in the hood 
1. Sterilize latex sleeves: Sonicate 1 hr in Branson, 1 hr in water, then soak in 70% 
isopropanol for at least 4 days 
2. Autoclave the following: bioreactor jars and lids with 3 way valves, ULTEM 
end pieces, scissors, fine tweezers, ½ inch Teflon tape, cable ties (2 per 
bioreactor), male and female luer lock caps, Masterflex tubing 
3. At least 1 hour before bioreactor mounting, lay out latex sleeves on a sterile 
drape in the hood, and allow the isopropanol to evaporate. 
4. Working with sterile gloves on, in the hood, wrap the ULTEM end pieces with a 
single layer of Teflon tape 
5. Place the latex tube over one end piece, and secure with a cable tie 
6. Remove a VRE from its mandrel carefully, trying to avoid putting undue stress 
on the tissue 
7. Use sterile scissors to cut off the Dacron cuffs from both ends of the tissue 
8. Slide the tissue over the latex – sometimes wetting the latex with medium helps 
this process 
9. Cut the latex to the appropriate length 
10. Place the other end cap in the latex tubing and secure with a cable tie 
11. Attach upper end piece to jar lid 
12. Use a 24 mL (or larger) syringe to pump medium in through the 3-way valve to 
fill the tubing and lumen of the latex sleeve – try to remove all air bubbles from 
the construct interior 
13. Fill bioreactor jar with medium (~220 mL DMEM+10%FBS+) 
14. Screw lid tightly onto jar 
15. Attach sterile syringe filter to port on jar lid 
16. Cap top of 3-way valve before placing the bioreactor jar into the incubator 
(37°C, 5% CO2, 95% relative humidity) 
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17. Fill lines: Using large (>30 mL) syringe, fill lines with medium. Cap one end, 
and place medium-filled smaller syringe on the other end (usually 5 or 10 mL 
syringe) 
18. Place tubing in through side point of the incubator and connect to 3-way valve 
on bioreactor jar 
19. Secure syringe in reciprocating syringe pump and start the pump  
20. Watch carefully for leaks over the first 30 minutes 
Equipment and Reagents: 
Name Company Product Number 
Masterflex PharMed BPT 
Tubing 
Cole-Parmer EW-06508-16 
Bioreactor jar (Tall 250 mL 
jar) 
Nalgene (ports added 
using Dremel) 
 
ULTEM end pieces McMaster Carr (machined 
by CSE shop) 
 
Teflon tape, Commercial 
Grade, ½” 
TaegaSeal  
Scissors Ustores  
Fine tweezers Ustores  
Sterile drape MediChoice MDRP1001 
Sterile gloves Medline Industries  
Sterile  syringes Norm-ject  
Cable ties McMaster Carr  
3 way valve Nordson Medical DCV125-001 
Sterile syringe filter Millex SLGP033RS 
Male and female luer lock 
caps 
Value Plastics Female: FTLLP-1 
Male: LP4-1 
Syringe pump Various, modified by CSE 
shop 
 
Incubator Nuaire 5500 
DMEM Gibco by Life 
Technologies 
11995-065 
FBS (fetal bovine serum) Hyclone Lot AXK51176 
Antibiotic/Antimycotic Gibco 15240-062 
Insulin Sigma I9278 
Ascorbic Acid Sigma A5960-100G 
 
